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ABSTRACT 
 
The development and survival of multicellular organisms depends upon the ability 
of cells to move.  Embryogenesis, immune surveillance, wound healing, and metastatic 
disease are all processes that necessitate effective cellular locomotion.  Central to the 
process of cell motility is the family of integrins, transmembrane cell surface receptors 
that mediate stable adhesions between cells and their extracellular environment.  Many 
human diseases are associated with aberrant integrin function.  Carcinoma cells in 
particular can hijack integrins, harnessing their mechanical and signaling potential to 
propagate cell invasion and metastatic disease, one example being integrin α6β4.  This 
integrin, often referred to simply as β4, is defined as an adhesion receptor for the laminin 
family of extracellular matrix proteins.  The role of integrin β4 in potentiating carcinoma 
invasion is well established, during which it serves both a mechanical and signaling 
function.  
miRNAs are short non-coding RNAs that regulate gene expression post-
transcriptionally, and data describing the role of extracellular stimuli in governing their 
expression patterns are sparse.  This observation coupled to the increasingly significant 
role of miRNAs in tumorigenesis prompted us to examine their function as downstream 
effectors of β4, an integrin closely linked to aggressive disease in breast carcinoma.  The 
work presented in this dissertation documents the first example that integrin expression 
correlates with specific miRNA patterns.  Moreover, integrin β4 status in vitro and in vivo 
is associated with decreased expression of distinct miRNA families in breast cancer, 
iv 
namely miR-25/32/92abc/363/363-3p/367 and miR-99ab/100, with purported roles in cell 
motility.  Another miRNA, miR-29a, is significantly downregulated in response to de 
novo expression of β4 in a breast carcinoma cell line, and β4-mediated repression of the 
miRNA is required for invasion.  Another major conclusion of this study is that β4 
integrin expression and ligation can regulate the expression of SPARC in breast 
carcinoma cells.  These data reveal distinct mechanisms by which β4 promotes SPARC 
expression, involving both a miR-29a-mediated process and a TOR-dependent 
translational mechanism.  Our observations establish a link between miRNA expression 
patterns and cell motility downstream of β4 in the context of breast cancer, and uncover a 
novel effector of β4-mediated invasion.    
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CHAPTER I  
INTRODUCTION 
 
Cell Motility 
The development and survival of multicellular organisms depends upon the ability 
of cells to move.  Embryogenesis, immune surveillance, wound healing, and metastatic 
disease are all processes that necessitate effective cellular locomotion (1).  Nearly all 
cells accomplish this intricate task by employing similar mechanisms.  In basic terms, 
receptors in cellular protrusions establish connections with extracellular matrix proteins 
at the leading edge of cells.  Stabilization of these adhesions generates traction.  
Contraction of the cell body followed by disassembly of adhesive contacts at the trailing 
edge permits translocation and cell propulsion in the forward direction.  Migration, thus, 
requires coordinated adhesion and detachment of nucleated contacts (2).  
Several adhesive complexes have been implicated in motility, including nascent 
adhesions, focal complexes, and focal adhesions.  Both nascent adhesions and focal 
complexes are small dynamic structures located near the leading edge and mediate 
signals important for actin polymerization (3, 4).  These structures exist transiently and 
are either rapidly disassembled or mature into focal adhesions, large sites of 
mechanotransduction (5).  These sites serve as signaling platforms and establish 
connections to the actin cytoskeleton through associations with structural proteins like 
talin, α -actinin, and vinculin (6).  Focal adhesions are present in both central and 
peripheral regions of the cell at the ends of long actin filament bundles (6).  Formation 
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and turn over of adhesions is mediated by the catalytic activity of enzymes such as focal 
adhesion kinase (FAK) and Src family kinases (SFKs) (6).  Signals from these molecules 
and others converge upon the RhoGTPase family of signaling molecules present in 
protruding motility structures.  These proteins mediate actin polymerization and novel 
adhesion formation (7).  Regulation of cytoskeletal organization and cell morphology is 
coupled to activation of signaling cascades that drive changes in gene expression and cell 
survival.  Central to these processes is the family of transmembrane glycoproteins called 
integrins. 
 
The Integrin Family 
Overview 
Integrins belong to a family of heterodimeric transmembrane cell surface 
receptors that mediate stable adhesions between cells and their extracellular environment.  
They are expressed across metozoa and likely evolved prior to the Cambrian explosion as 
a requirement for multicellularity, permitting adhesion of cells to basement membranes 
essential for the development of multilayered organisms (8, 9).  Their history of 
discovery nearly thirty years ago was protracted by both technical limitations and 
conceptual challenges—cell biologists in search of the fibronectin receptor were 
confounded by our current understanding that integrins bind multiple ligands, and that 
most ligands are recognized by several integrin family members.  Ultimately, the use of 
monoclonal antibodies, affinity chromatography, and crosslinking uncovered this novel 
family of cell surface receptors.  Richard O. Hynes, a British cell biologist at the forefront 
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of these discoveries, coined the term integrin, a name reflecting the role of these integral 
membrane proteins in maintaining the integrity of connections between the cytoskeleton 
and extracellular matrix (9, 10).   
These adhesion receptors link the actin cytoskeleton (with the exception of 
integrin α6β4) to components in the extracellular matrix, including laminin, collagen, 
fibronectin, vitronectin, and fibrinogen (11).  A role for integrins has also been 
established in mediating cell-cell adhesion.  Eighteen α subunits and 8 β subunits have 
been identified in mammalian cells.  Despite the potential for a sizeable number of 
heterodimers, selectivity of many α subunits in their association with a single β subunit 
limits the family of receptors to only 24 unique heterodimeric pairs.  Ligand specificities 
and phenotypes from knockout studies in mice indicate that each integrin has a unique 
nonredundant function (8).  Integrins are composed of one α and one β subunit, both of 
which are single pass transmembrane proteins linked together non-covalently through 
large ectodomains.  Functional studies demonstrate that truncated integrin subunits 
lacking either the transmembrane or cytoplasmic domains still form heterodimers (12).  
Many cytoplasmic domains have alternative splice variants and, with the exception of the 
β4 subunit, all are relatively short (13). 
Structure 
In simple structural terms, integrins consist of a globular extracellular head 
formed by both subunits from which two stalks extend and penetrate the plasma 
membrane.  Both α and β subunits are extensively disulfide bonded.  The ectodomain of 
each subunit is architecturally complex.  At their N-terminus, all α subunits contain seven 
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repeats of cysteine-rich segments folded into a seven-blade β -propeller (14).  This 
domain constitutes the bulk of the α head domain and mediates the essential interface 
with the β subunit (15).  Half of α subunits contain an insert (I) or von Willebrand factor 
A domain, which is positioned within the β -propeller if present (16).  This α I domain 
spans 200 amino acids in length and houses a divalent cation (Mg++) ligated by three 
loops of secondary amino acid structure, which constitute the metal ion-dependent 
adhesion site (MIDAS) (17).  The MIDAS is critical for metal binding and, thus, integrin 
function, as divalent cations are universally required for integrins to bind their cognate 
ligands (15).  C-terminal to the head is the leg of the α subunit composed of three β -
sandwich domains: the thigh constitutes the upper leg, while calf-1 and calf-2 domains 
make up the lower leg.  A small Ca++ binding loop is located between the thigh and calf-1 
domains.  This position is referred to as the genu (French for knee) and is the pivot point 
for α subunit extension (15).   
The β subunits are structurally more complex.  The β head consists of PSI 
(plexin/semaphorin/integrin), hybrid, and β I domains.  The β I domain is situated in the 
PSI domain, which is located within the hybrid domain.  Spanning about 240 amino acids 
in length, this highly conserved β I domain is analogous to α I domain but is composed of 
two additional segments: the specificity-determining loop (SDL) involved in ligand 
binding and an interface domain that interacts with the β-propeller of the α subunit (15).  
The β I domain contains a MIDAS that binds negatively charged residues, which in turn 
bind the Mg++ in the α I domain (17).  Two adjacent metal binding sites termed 
synergistic metal ion binding site (SynMBS) and the adjacent to metal ion-dependent 
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adhesion site (ADMIDAS) are present and both bind Ca++ (15).  C-terminal to the hybrid 
domain is the leg of the β subunit, a cysteine-rich segment containing four integrin 
epidermal growth factor-like (I-EGF) domains, a β-ankle, and a β-tail domain.  The knee 
is located between I-EGF domains 1 and 2. 
The transmembrane domains of integrin subunits are believed to associate via a 
ridge-in-groove packing model involving an α-helical interface in the resting state (15).  
A salt bridge linking the two subunits has also been proposed (18).  Cytoplasmic domains 
are believed to associate very weakly with one another if at all.   
Bidirectional Signaling 
Integrin ectodomains are thought to equilibrate between three conformational 
states: bent conformation with a closed headpiece, intermediate extended conformation 
with a closed headpiece, and extended conformation with an open headpiece.  Such 
conformations roughly correspond to low affinity, primed and activated, and ligand-
bound activated integrin states, respectively (19).  In the closed conformation, the 
ectodomain of the integrin is bent and juxtaposed to the plasma membrane.  This 
confirmation is stabilized tenuously by interactions between the α and β legs, the head 
domain and both lower legs, and the α and β transmembrane domains (17, 20).  
Conformational changes producing destabilization of these interactions can be induced 
upon association of effector molecules, such as talin, with the cytoplasmic tail, which link 
the integrin to the cellular cytoskeleton.  Mutations in the cytotail can also destabilize the 
bent conformation (18, 21-23).  These events cause separation of the legs within the 
transmembrane segment, extension of the head in a switchblade-like motion, and swing-
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out of the hybrid domain (17).  This conformational change primes or activates the 
integrin for ligand binding.  The concept of integrin priming is known as inside-out 
signaling, because intracellular events induce conformational changes of integrin 
ectodomains to facilitate ligand-binding with greater affinity (19).   
In α subunits that express the I domain, this structure functions as the major 
ligand binding domain, while the β I domain regulates ligand-binding activity of the α I 
domain.  In integrins lacking the α I domain, the β I domain MIDAS directly binds the 
ligand.  During cell adhesion or migration, tensile forces transmitted from a ligand-bound 
integrin are resisted by the cytoskeleton and associated adapter molecules bound to the 
cytoplasmic tail.  Such resistance stabilizes the headpiece and favors an extended 
conformation over bent or closed positions (17).  Ligand-binding affinity and 
adhesiveness of integrins are generally enhanced by increasing concentrations of 
extracellular Mn++ and decreasing concentrations of extracellular Ca++ (17).  Binding of 
the large multivalent ligands promotes lateral association of integrin heterodimers into 
oligomers on the cell surface known as clustering.  Close proximity of integrin 
cytoplasmic domains results in kinase recruitment and activation of intracellular signaling 
cascades, often referred to as outside-in signaling (19).  
The bi-directional signaling capacity intrinsic to integrins results in a wide range 
of biological consequences.  For example, inside-out signaling is critical for establishing 
adhesive strength between integrins and their extracellular environment, permitting 
transfer of tensile force required for integrin-mediated cell adhesion and extracellular 
matrix remodeling.  Outside-in signaling, on the other hand, drives activation of signaling 
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cascades involved in cellular processes such as cytoskeletal organization, gene 
expression, and cell differentiation.  Though distinct processes, these two directions of 
integrin signaling are closely linked and often converge upon complex cellular processes, 
a key example being the coordination of cell motility. 
The Cancer Connection 
Integrins regulate cell migration in variety of physiological and pathological 
contexts.  Many diseases, including autoimmune disorders and cancer, are associated 
with aberrant integrin function.  Carcinoma cells in particular can hijack integrins, 
harnessing their mechanical and signaling potential to propagate cell invasion and 
metastatic disease.  In this context, cells can move singularly or as sheets of cells linked 
together by cell adhesion molecules (24).  The morphology of a single migrating cell is 
mesenchymal, arising from a presumed epithelial-to-mesenchymal transition (EMT) 
occurring in response to stimuli from the tumor microenvironment of carcinoma cells.  
Specifically, downregulation of molecules that establish cell-cell adhesions, such as 
cadherins, induces changes in cytoskeletal organization and signaling pathways that 
allow neoplastic cells to dissociate from the primary tumor (1).  
 Dissemination of malignant cells and subsequent metastasis depend upon 
coordination of migratory and proteolytic processes.  Four cell protrusions at the leading 
edge of motile cells have been described: lamellipodia, filipodia, invadopodia, and blebs 
(7).  Tumor cells are unique in their ability to form invadopodia, sites of rapid actin 
polymerization and associated proteins, including Wiskott-Aldrich syndrome proteins 
(WASP), Rho GTPases, SFKs, and the actin nucleating Arp 2/3 complex (6).  Inherent to 
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these actin-rich complexes is the potential to degrade surrounding matrix through 
proteolysis.  Clearly this ability is critical for carcinoma cell invasion through basement 
membranes and stromal tissue and into blood vessels (25).  At the forefront of these 
motility structures, integrins mediate the dynamics of cell morphology and adhesion in 
migrating cells. 
The field of integrin biology has evolved since its inception nearly thirty years 
ago.  Richard O. Hynes was credited with the discovery of integrins despite never 
intending to pursue a scientific career centered on cell adhesion.  Rather, he began his 
research endeavors looking for differences on the cell surface of normal and tumor cells 
(9).  Perhaps appropriately, fruitful extensions of his early work established a critical role 
for these cell surface receptors in promoting tumor progression.  One such example is 
integrin α6β4. 
 
The α6β4 Integrin 
Discovery 
In 1986, an Italian group reported the identification of a tumor associated 
glycoprotein complex termed TSP-180 on the surface of murine lung carcinoma cells that 
correlated with metastatic potential (26).  Antibody characterization of the complex 
subsequently established preferential expression of this protein in malignant tumors 
relative to normal tissue in both humans and mice (27).   
The following year, a group from the Netherlands described a novel noncovalent 
complex of glycoproteins Ic and IIa on the surface of intact platelets and postulated a role 
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for this complex in cell adhesion (28).  The IIa subunit of this complex was ultimately 
determined to be identical to the β subunit of the family of human VLA (very late 
antigen) cell surface receptors (later recognized as integrins) by a group at Harvard (29, 
30), and the complex was designated VLA-6 (31).  Further characterization using 
antibodies to the IIa subunit, which would later come to be called β1, revealed a novel 
binding partner for the Ic subunit (corresponding to α6) of this complex from a mouse 
mammary epithelial tumor (32).  This subunit was termed IcBP (or Ic binding partner) 
and noted to have marked similarities to the extracellular matrix protein laminin (32).  
The IcBP was coined β4, and additional characterization of this novel VLA subunit was 
carried out by the American and Dutch groups, culminating in the first published report 
of the heterodimeric cell surface receptor α6β4 (33).     
By 1989, it became apparent that the metastatic marker TSP-180 identified by 
Falcioni and colleagues bore striking resemblance the newly identified superfamily of 
adhesion receptors called integrins, in particular to the α6β4 integrin.  Collaborative 
efforts confirmed the speculation and established TSP-180 to be the recently identified 
α6β4 integrin (34).  This discovery coincided with an independent publication from a 
group out of California providing evidence of a novel integrin family member on the 
surface of human epithelial cells termed αEβ4 (35).  Thus began a research pursuit 
spanning three decades aimed at further characterizing the adhesion receptor α6β4 
integrin and defining its role in development, homeostasis, and pathology.       
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Structure and Development 
The α6β4 integrin is often referred to simply as β4, since α6 is the only partner 
with which it heterodimerizes.  β4 integrin is conserved across the metazoan kingdom 
and is expressed predominantly in epithelial cells, though reports have identified the 
integrin on fibroblasts, thymocytes, and Schwann cells (36).  β4 integrin is defined as an 
adhesion receptor for the laminin family of extracellular matrix proteins and joins α3β1, 
α6β1, and α7β1 as one of the four commonly known laminin-binding integrins.  α2β1 has 
also been shown to bind laminin despite functioning predominantly as a collagen receptor 
(37).  Though β4 is promiscuous in its association with various laminin isoforms, 
epidermal laminin-332 (previously called laminin-5) in the basement membrane is the 
preferred ligand for the integrin (38).  Integrin biologists established early on that β4 was 
unique among β integrin subunits.  Several defining qualities distinguish β4, including its 
ability to bind keratin intermediate filaments, as well as its unusually long cytoplasmic 
tail.  While β subunit intracellular domains typically consist of 50 amino acids, the β4 
cytoplasmic domain exceeds 1000 amino acids in length.  Two pairs of type III 
fibronectin (FNIII) repeats separated by a connecting segment characterize the 
cytoplasmic tail.  A Na+-Ca++ exchanger (CalX) motif with unknown function is situated 
membrane-proximal to the first FNIII repeat.  These cytoplasmic domains house multiple 
serine, cysteine, and tyrosine residues that are critical for β4 function.   
Expression of β4 has been localized to the basal surface of epithelial cells in 
junctional adhesion complexes called hemidesmosomes (HDs), inert structures that link 
cells through their intermediate filament cytoskeleton to laminins in the basement 
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membrane.  This adhesive function is critical for establishing epithelial integrity, as 
mutational studies and patient case reports link dysfunction of the integrin to pyloric 
atresia associated with the junctional variant of a blistering skin disease called 
epidermolysis bullosa (39).  Knockout studies in mice corroborate these data; pups 
lacking expression of the integrin die shortly after birth due to detachment of the 
epidermis occurring in response to mechanical stress (40, 41).   
Role in Hemidesmosome Organization 
Further investigation has revealed that β4 plays a pivotal role in the organization 
of HDs.  The current model of HD assembly involves an initial dephosphorylation event 
on the β4 cytoplasmic domain by an unknown phosphatase that induces a conformational 
change to expose binding sites in the FNIII repeats (38).  β4 then recruits plectin, which 
associates via its actin binding domain with the first pair of FNIII repeats (42, 43).  
Reinforcement of this connection is accomplished through additional interactions of the 
plectin plakin domain with both the connecting segment and C-terminal end of the β4 
cytoplasmic tail (44).  Bullous pemphigoid (BP) 180 is then recruited and binds laminin 
extracellularly while associating with the third FNIII repeat and plectin intracellularly 
(45).  Finally BP230 binds to both β4 and BP180 (45).  In addition to the connections 
established by the β4 cytoplasmic domain, the ectodomain of α6 interacts with the 
tetraspanin CD151 (46).  This classic or Type I HD, characteristic of basal epidermal 
cells, establishes connections to the intermediate filament system through both BP230 
and plectin (38).  Our understanding of HD organization stems largely from studies 
investigating the molecular consequences of human mutations in genes expressing α6, β4, 
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plectin, and BP180.  Careful dissection of patient phenotypes and in vitro studies have 
established that β4 interaction with plectin is required for proper HD formation, and that 
assembly of these adhesion complexes can occur independently of the natural β4 ligand 
laminin-322 (42, 43, 47-50).    
Role in Carcinoma Invasion 
The process of invasion involves enzymatic degradation of the basement 
membrane followed by cell migration through the unobstructed path, thus the ability to 
migrate is inherent to an invasive carcinoma cell (51).  It has been well established that 
β4 integrin can mediate carcinoma invasion, as exogenous expression of the integrin 
confers an invasive phenotype in both rectal and breast carcinoma cells (52, 53), while 
depletion of the integrin impedes chemoinvasion in metastatic breast carcinoma cells 
(54).  Early studies linking increased expression of β4 to aggressive tumors and poor 
prognosis (27, 55, 56) initially proved puzzling, however, given its established role in 
mediating epithelial integrity coupled to the observation that most carcinomas lack HDs 
(57).  Research during the past decade has explored this paradigm and revealed a novel 
role for the integrin in regulating cytoskeletal dynamics and carcinoma invasion, 
functions dependent upon key post-translational modifications of the β4 cytoplasmic tail.     
Recent studies have explored the mechanism by which β4 transitions from a 
mechanical adhesion device to a signaling competent receptor in motility structures and 
have established a critical role for the phosphorylation of key serine residues.  These 
phosphorylation events can occur in response to stimulation by growth factors, such as 
epidermal growth factor (EGF) or macrophage-stimulating protein (MSP) (58-60).  For 
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example, EGF stimulation of carcinoma cells has been shown to induce protein kinase C 
(PKC)-α-mediated phosphorylation of three serine residues (S1356, S1360, S1364) on 
the β4 cytoplasmic tail, disrupting HDs and releasing the integrin from sites of adhesion 
on the basal surface of epithelial cells (59).  Similar observations have been extended to 
keratinocytes (58, 60).  A recently identified constitutively phosphorylated serine, S1424, 
on the cytoplasmic tail also appears to play a role in the disassembly of HDs (61).  These 
phosphorylation events precede β4 mobilization to the leading edge in lamellae and 
filipodia, where the integrin engages F-actin and promotes migration of carcinoma cells.  
Again, the ability of β4 to promote motility is not unique to carcinoma cells, as 
keratinocytes employ the integrin during migration in wound healing.  The mechanism by 
which β4 engages F-actin, however, remains undefined.  Since the cytoplasmic tail of this 
integrin lacks a consensus actin-binding motif, the interaction is likely indirect and 
involves a linker protein such as plectin (62). 
Biophysical analyses characterizing the microdomains of these motility structures 
reveal β4 residence within tetraspanin-enriched complexes and highlight a role for 
palmitoylation of key cysteine residues in the recruitment of β4 to these compartments in 
the plasma membrane.  Investigation of β4 palmitoylation arose during a study of the 
palmitoylated tetraspanin CD151, which is known to interact closely with β4 and has 
been implicated in the formation of HDs.  Data published from these studies provide 
compelling evidence that palmitoylation of the β4 cytoplasmic tail is critical for 
recruitment of CD151 and β4 to tetraspanin-enriched microdomains and plays a key role 
in promoting cell spreading and signaling (63).  These observations sharply contrast 
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previous reports that β4 palmitoylation recruits the integrin to lipid rafts (64).  
Localization of β4 within these tetraspanin webs (65) likely augments its signaling 
function through close proximity to other palmitoylated signaling molecules.  
Mobilization of β4 to motility structures precedes initiation of signaling events 
that occur in response to ligand binding and association with other growth factor 
receptors.  As aforementioned, the unusually long cytoplasmic domain of β4 integrin 
distinguishes it among integrins, prompting curiosity as to its biological role.  Clearly one 
function involves its ability to serve as a signaling platform, initiating various signaling 
cascades that mediate chemotactic responses involved both in maintaining normal tissue 
homeostasis, such as in wound healing, as well as in promoting carcinoma cell motility 
during tumor progression.  At the nexus of these intracellular signaling events is 
phosphatidolinosital-3 kinase (PI3K), the most critical mediator of β4-regulated 
carcinoma invasion.  Much effort has been invested in defining the mechanisms by which 
this lipid kinase orchestrates signaling events downstream of the integrin, culminating in 
the identification of key tyrosine residues on the β4 cytoplasmic tail essential for 
executing its function.  Specifically, six tyrosine residues (Y1257, Y1422, Y1440, 
Y1494, Y1526 and Y1642) have been reported to participate in β4-mediated signaling 
events (38, 66).  Tyrosine 1494 has emerged as the master regulator of β4 
phosphorylation and signaling, as mutational analyses have demonstrated that 
phenylalanine substitution at this site reduces overall tyrosine phosphorylation and 
impedes β4-mediated functions, including carcinoma cell survival, migration and 
invasion, as well as anchorage independent growth, tumor development, and 
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angiogenesis (67, 68).  Mechanistic work revealed that Y1494 is required for 
phosphorylation of the insulin receptor substrate 2 (IRS-2), which subsequently binds to 
the p85 regulatory subunit of PI3K and activates signaling in response to β4 ligation (67).  
Furthermore, this tyrosine residue is located within a consensus binding motif for the 
SH2 domain of tyrosine phosphatase SHP-2, which binds β4 and activates SFKs 
upstream of PI3K, events that are also required for the invasive phenotype of carcinoma 
cells (69-71).   
The role of targets downstream of PI3K in promoting carcinoma invasion has 
been well established.  The pioneering study establishing that β4 signals through this 
pathway also identified a positive role for the Rho GTPase Rac downstream of PI3K in 
chemoinvasion (53).  This small G protein has also been shown to regulate the migratory 
behavior of keratinocytes (50).  Subsequent studies characterized the functions of distinct 
Akt isoforms, highlighting a role for Akt2 in promoting carcinoma motility (72, 73).  
Extensions of this work have investigated various NFAT (nuclear factor of activated T 
cells) family members and defined roles for both NFAT1 and NFAT5 in promoting 
carcinoma invasion, in part through increased transcription of motility factors 
autotaxin/ENPP2 and S100A4/metastatin (72-77). 
Other β4-mediated signaling molecules facilitate carcinoma invasion 
independently of the PI3K cascade.  Specifically, β4 promotes the formation of lamellae 
and cell motility in carcinoma cells through inhibition of intracellular cAMP levels, 
which are repressed by a cAMP-specific phosphodiesterase (78).  A related study also 
demonstrated a role for cAMP metabolism in the RhoA-mediated cell motility 
15
downstream of β4 occurring independently of Rho GTPase family member Rac1 (79).  
Finally, MSP-dependent phosphorylation of the β4 cytoplasmic tail has been shown to 
induce p38 and NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) 
signaling to promote wound healing in keratinocytes (58).  Though these studies were 
conducted using immortalized skin cells, it is feasible that this mechanism of cell motility 
could contribute to the progression of invasive carcinomas. 
In addition to its regulation of pro-invasive factors, β4 has also been shown to 
directly transmit mechanical forces from the acto-myosin system that can presumably 
propel carcinoma cells during the invasive process (80).  Using traction force detection 
assays, Rabinovitz et al. demonstrated that the integrin transmits forces on either laminin-
111 or antibody to the α6 subunit.  Compression forces generated by the integrin remodel 
the basement membrane, a process dependent upon activation of both PI3K and RhoA; 
these two signaling pathways have been implicated in β4-dependent carcinoma invasion 
(53, 79).  An important conclusion stemming from this work involves the observation 
that β4 can function independently of other integrins to impact extracellular matrix 
organization and drive chemoinvasion. 
Despite an abundance of literature establishing a functional role for the integrin in 
promoting cell motility, β4 is not an island.  Association with growth factor receptors is 
believed to augment β4-mediated signaling and carcinoma invasion.  Initial reports 
documenting β4 interaction with growth factor receptors described cooperative 
associations with members of the EGF family of receptors, including EGFR, ErbB2, and 
ErbB3 (81-84).  Of note, these early studies relied heavily on the results of co-
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immunoprecipitation experiments, which are often difficult to accurately interpret due 
either to the transient nature of β4 interactions with other molecules or the fact that β4 
resides in protein-rich microdomains, and molecules pulled down by such assays may not 
physically interact with the integrin (85).  Nonetheless, Falcioni and colleagues 
demonstrated β4 association with the orphan ErbB2 receptor in breast carcinoma cells, 
and a role was subsequently established for this association in the activation of PI3K 
signaling and carcinoma invasion (83).  It has also been established by various groups 
that interactions between β4 and EGFR promote HD disassembly and β4-mediated 
carcinoma cell invasion, suggesting a role for effector signaling molecules downstream of 
the integrin including Fyn and Rho (81, 86, 87).  β4 association with c-Met has also been 
documented, and data from this work describe a novel role for β4 as a signaling adapter 
molecule that enhances hepatocyte growth factor (HGF)-induced carcinoma invasion 
(88).  The physical interaction between these two cell surface receptors remains 
controversial, however, and more recent evidence suggests that both can facilitate 
carcinoma invasion independently of one another (89).  The first biophysical evidence 
linking β4 to a growth factor receptor arose from investigation of human epidermal 
wound healing as briefly described above, in which MSP stimulation of Ron was shown 
to induce PI3K-mediated phosphorylation of both Ron and the β4 cytoplasmic tail.  
These phosphorylation events in turn generate binding sites that permit formation of a 
heterotrimeric complex in which β4 associates with Ron presumably via 14-3-3 proteins.  
Formation of this complex displaces β4 from HDs to lamellae and facilitates keratinocyte 
migration and wound closure (58).  Although these studies were not conducted in a 
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cancer model, such interactions parallel events observed in carcinoma cells with respect 
to growth factor-induced disassembly of HDs and relocalization of β4 to motility 
structures at the leading edge.  Similar mechanisms could, thus, be at play in the 
progression of invasive carcinoma cells. 
Trafficking 
Integrin trafficking plays a critical role in chemoinvasion, as well as cell adhesion, 
spreading, and migration (90).  This process is characterized by integrin delivery to the 
cell surface, receptor internalization, and recycling of the internalized integrin.  As such, 
this cycle mediates disassembly of adhesive complexes, matrix turnover, and the 
formation of new focal contacts on the leading edge of migrating cells (90).  Little is 
known about β4 trafficking, though studies conducted during the past decade have shed 
some light on the subject.  One group reported that hypoxia promotes the invasion of 
breast carcinoma cells through stabilization of microtubules and increased trafficking of 
β4 to the cell surface, a process mediated by small G protein Rab family member Rab-11 
(91).  Another group demonstrated that arrestin family member ARRDC3 interacts with 
the β4 subunit to induce integrin internalization, ubiquitination, and subsequent 
degradation (92).  Moreover, expression of ARRDC3 is downregulated in breast 
carcinomas, consistent with the observation that β4 plays a role in promoting aggressive 
disease (92).   
Role in Other Biological Functions 
In addition to its ability to promote cell migration and invasion, β4 has been 
linked to tumor cell survival, anchorage independence, and tumor initiation.  A functional 
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link between the integrin and survival was born from the observation that breast 
carcinoma cells expressing β4 could evade apoptosis under serum- and matrix-
deprivation conditions, and that this survival mechanism was dependent upon β4 
activation of the PI3K signaling pathway (93).  Interestingly, this phenomenon only 
occurs in cells expressing mutant p53, as the wild-type tumor suppressor induces 
caspase-3-dependent cleavage and inactivation of Akt in response to β4 expression and 
ligation (94).  Along these lines, mammalian target of rapamycin (mTOR) has been 
shown to function downstream of PI3K to promote β4-mediated survival via a 
mechanism involving upregulation of vascular endothelial growth factor (VEGF) cap-
dependent translation (95).  A continuation of this work demonstrated that β4 regulates 
tumor cell survival in vivo dependent upon VEGF (96).  Recent data has shown that β4 
upregulates ErbB3 expression and formation of the ErbB2/ErbB3 heterodimer, which is 
required for β4-mediated activation of PI3K and breast carcinoma cell evasion of 
apoptosis (84).  Utilization of three-dimensional model systems has further contributed to 
our understanding of β4 function in carcinoma survival and demonstrated that β4-induced 
polarity of breast carcinoma cells promotes evasion of apoptosis via an NFκB-dependent 
mechanism (97).  An extension of this work uncovered a laminin-332 autocrine loop, by 
which cells secrete their own extracellular matrix protein leading to β4-dependent 
activation of Rac and NFκB that promotes anchorage-independent carcinoma cell 
survival (98). 
Recent attention has been directed toward the ability of β4 to promote tumor 
initiation, a phenomenon studied largely in the context of squamous cell carcinoma.  Data 
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from a murine model of Ras-driven invasive epidermal carcinoma identified a role for β4 
and laminin-332 in promoting tumor formation (99).  Another murine model using 
targeted expression of β4 to the suprabasal layer of the epidermis demonstrated that the 
integrin suppresses transforming growth factor (TGF)-β-mediated growth inhibition, 
resulting in increased formation of both benign and malignant tumors induced by 
chemical carcinogenesis (100).  These data mesh with observations from mouse models 
of mammary tumorigenesis demonstrating that β4 and downstream effector VEGF can 
promote tumor initiation (96), and that depletion of β4 in a breast carcinoma cell line 
reduces tumor uptake (101).  Moreover, another group established a role for β4 signaling 
in mediating tumor initiation in a mouse model of ErbB2-induced mammary carcinoma 
(102). 
Ligand Independence 
While ligand binding is central to the activation of integrin signaling and 
downstream effects on cell behavior, data from the field provide compelling evidence 
that β4 can function in a ligand-independent manner.  Early studies revealed that 
expression of β4 in a rectal carcinoma cell line endogenously devoid of the integrin 
promotes growth arrest, invasion, and cell spreading independent of adhesion to laminin 
(52, 103).  Furthermore, β4 has been shown to promote migration in a breast carcinoma 
cell line on a collagen matrix (78).  Such studies do not negate the possibility, though, 
that ligation occurs in response to endogenous laminins secreted by carcinoma cells.  
More compelling evidence relies on data generated from carcinoma cells expressing a 
trunctated β4, which lacks the extracellular binding domain but retains signaling capacity 
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and confers an invasive potential equivalent to that of wild-type β4 (88).  Several 
hypotheses have been proposed to explain these observations, including the possibility 
that clustering of β4 cytoplasmic domains initiates signaling or that constitutive 
activation of adhesion-dependent signaling pathways in transformed cells confers a 
survival advantage for tumor cells in the absence of their natural ligand (78, 88, 103, 
104).  
 
microRNAs 
Overview 
In 1993, Victor Ambros identified a defective gene responsible for a mutant 
phenotype known as the “bag of worms” in the nematode worm C. elegans.  The 
unfortunate developmental defect was characterized by the accumulation of fertilized 
eggs that ultimately hatch within the mutant worm.  Surprisingly, the gene did not encode 
a protein but a short RNA named lin-4 that was shown to negatively regulate the 
expression of another gene called lin-14 by binding to the 3’ untranslated region (UTR) 
of its transcript to block translation (105, 106).  Nearly a decade later, the scientific 
community recognized that small snippets of RNA, termed microRNAs (miRNAs), could 
regulate cellular processes, a discovery that transformed our understanding of genetics, 
development, and human disease.    
miRNAs are short single-stranded non-coding RNAs that mediate post-
transcriptional gene expression.  This class of regulatory molecules recognizes and binds 
complementary sequences on target mRNAs to induce transcript degradation or 
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translational inhibition.  Hundreds of miRNAs have been identified and extensive 
research conducted during the past two decades has characterized their biogenesis, 
regulation of target genes, and contributions to disease. 
Biogenesis  
miRNAs may be independent transcriptional entities or located in clusters with 
other miRNAs.  Some may be positioned in the introns of protein coding genes (107) and 
share transcription patterns with their host gene when found in a sense orientation (108, 
109).  miRNAs are transcribed from genomic DNA by RNA polymerase II into a 
precursor that folds back onto itself forming a characteristic stem-loop structure.  Primary 
transcripts of clustered miRNAs contain multiple hairpins.  The double-stranded RNA 
contained in this primary miRNA (pri-miRNA) is recognized by DiGeorge Syndrome 
Critical Region 8 (DGCR8), which associates with the RNase III endonuclease Drosha to 
form the microprocessor complex.  Cleavage two helical turns into the stem releases the 
hairpin from the loose ends of the primary transcript, yielding a precursor miRNA (pre-
miRNA) with a two-nucleotide overhang on the 3’ end (110-112).  Some unconventional 
miRNAs called mirtrons are cleaved directly out of the intron by splicing machinery and 
bypass the microprocessor (113-115).  This pre-miRNA is then exported by the 
nucleocytoplasmic shuttle exportin-5 from the nucleus where the RNase III endonuclease 
Dicer cleaves the loop from the hairpin (116-119).  The resulting double-stranded RNA is 
approximately 22 nucleotides in length and known as the miRNA-miRNA* duplex.  This 
duplex unwinds, and the mature miRNA is loaded into the miRNA-induced silencing 
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complex (miRISC), a multiprotein complex containing members of the Argonaut (Ago) 
family of proteins, while the miRNA* strand is degraded (108).  
Target Gene Regulation 
 miRNAs bind multiple targets, and genes, in turn, can be silenced by multiple 
miRNAs.  Over 500 mature miRNAs have been identified, many of which are grouped 
into families based on their conserved seed region, a sequence of nucleotides (2-7) at the 
5’ end of miRNAs that is most critical for target recognition.  Following maturation, a 
miRNA binds regions in the 3’UTR of target mRNAs complementary to its seed 
sequence.  Recent evidence suggests that rare alternative mechanisms of gene regulation 
do occur and include miRNA binding to the 5’UTR or open reading frame of target genes 
or even directly to DNA to block transcription (120-122).  Moreover, participation of the 
miRNA regions outside of the seed has also been reported to facilitate silencing of target 
genes (123, 124).  Perfect or near perfect complementarity between the miRNA and 
target promotes Ago2-mediated cleavage of the transcript, the predominant mechanism of 
gene silencing by miRNAs in plants.  Most mammalian miRNAs, however, bind 
imperfectly to target genes and induce translational inhibition and mRNA destabilization 
(123, 125). 
Contributions to Tumorigenesis 
 A role for miRNAs in the progression of tumorigenesis has been well established.  
Numerous studies have documented aberrant expression of miRNAs in tumors relative to 
normal tissues (126).  Dysregulation of miRNAs may occur in response to epigenetic 
changes that modify miRNA promoter methylation patterns or genetic alterations such as 
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chromosomal deletions.  Studies have also identified defects in processing machinery, 
resulting in widespread effects on miRNA expression.  For example, loss of Dicer 
function in breast cancer globally downregulates mature miRNA expression and 
promotes aggressive disease (127).  Many miRNAs have been identified as either 
oncogenes (often referred to as oncomiRs) or tumor suppressors based on their biological 
impact.  For example, members of the miR-200 family of miRNAs have been well 
characterized in this context and are known to be key regulators of the EMT (128), a 
precursor to invasion and metastasis.      
 
Overview and Objectives 
Integrins are key modulators of cell behavior.  They utilize connections with the 
extracellular matrix to communicate information about their microenvironment, thereby 
inducing signal transduction events that modify cytoskeleton dynamics and cell motility.  
The role of integrin β4 in potentiating tumorigenesis is well established, particularly in 
carcinoma invasion.  In this context, transformed epithelial cells infiltrate the basement 
membrane into local surrounding tissue, gaining access to lymph drainage and the 
vascular system.  This process, involving complex interactions between tumor cells and 
the extracellular environment, is a precursor to distant metastasis and patient mortality.  
Integrin β4 plays both a mechanical and signaling role in this capacity.  Studies on breast 
cancer have contributed most significantly to our understanding of how β4 contributes to 
the invasive process, though much remains to be seen.   
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The steps involved in miRNA biogenesis have been well characterized, though far 
less is understood about the processes governing their regulation.  Specifically, data 
describing the role of extracellular stimuli in modifying miRNA expression patterns are 
sparse.  Perhaps the most extensively explored example is the role of TGF-β in promoting 
the interaction of p68-interacting Smad proteins with the endocuclease Drosha to 
facilitate miRNA processing and maturation (129).  Along these lines, establishment of 
cell-cell contacts as measured by increasing confluence of cells in vitro has also been 
shown to enhance Drosha-mediated miRNA processing (130).  These observations 
coupled to the increasingly significant role of miRNAs in tumorigenesis necessitate 
additional investigation into the role of microenvironment in regulating miRNA 
expression and function in the context of cancer. 
Our interest in the ability of integrins to potentiate carcinoma migration and 
invasion in breast cancer prompted us to examine the role of miRNAs as downstream 
effectors of β4, an integrin closely linked to aggressive disease.  The work presented in 
the following chapters explores the role of β4 expression on miRNA patterns in the 
context of breast carcinoma invasion, and reveals a novel effector molecule downstream 
of the integrin. 
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CHAPTER II 
EFFECTS OF β4 INTEGRIN EXPRESSION ON MICRORNA PATTERNS IN 
BREAST CANCER 
 
This chapter represents work submitted as:  
Effects of β4 Integrin Expression on microRNA Patterns in Breast Cancer 
Kristin D. Gerson, V.S.R. Krishna Maddula, Bruce E. Seligmann, Jeffrey R. Shearstone, 
Ashraf Khan, and Arthur M. Mercurio 
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Abstract 
The integrin α6β4 is defined as an adhesion receptor for laminins.  Referred to 
simply as ‘β4,’ this integrin plays a key role in the progression of various carcinomas 
through its ability to orchestrate key signal transduction events and promote cell motility.  
To identify novel downstream effectors of β4 function in the context of breast cancer, 
miRNAs were examined because of their extensive links to tumorigenesis and their 
ability to regulate gene expression globally.  Two breast carcinoma cell lines and a 
collection of invasive breast carcinomas with varying β4 expression were used to assess 
the effect of this integrin on miRNA expression.  A novel miRNA microarray analysis 
termed quantitative Nuclease Protection Assay (qNPA) revealed that β4 expression can 
significantly alter miRNA expression and identified two miRNA families, miR-
25/32/92abc/363/363-3p/367 and miR-99ab/100, that are consistently downregulated by 
expression of this integrin.  Analysis of published Affymetrix GeneChip data identified 
54 common targets of miR-92ab and miR-99ab/100 within the subset of β4-regulated 
mRNAs, revealing several genes known to be key components of β4-regulated signaling 
cascades and effectors of cell motility.  Gene ontology classification identified an 
enrichment in genes associated with cell migration within this population.  Finally, gene 
set enrichment analysis of all β4-regulated mRNAs revealed an enrichment in targets 
belonging to distinct miRNA families, including miR-92ab and others identified by our 
initial array analyses.  The results obtained in this study provide the first example of an 
integrin globally impacting miRNA expression and provide evidence that select miRNA 
families collectively target genes important in executing β4-mediated cell migration. 
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Introduction 
Integrins belong to a family of heterodimeric transmembrane cell surface 
receptors composed of α and β subunits that mediate stable adhesions between cells and 
their extracellular environment (131, 132).  The integrin α6β4, referred to as ‘β4 
integrin,’ is an adhesion receptor for all of the known laminins.  In a homeostatic setting, 
β4 links the intermediate cytoskeleton to laminins in the basement membrane through 
structures called hemidesmosomes located on the basal surface of epithelial cells (133, 
134).  The role of this integrin evolves, however, under pathological conditions when β4 
is rendered signaling competent and assumes an active role in initiating various signaling 
cascades and facilitating cell motility.  This role is particularly striking in the context of 
tumorigenesis, where factors in the microenvironment of invasive carcinomas promote 
relocalization of β4 from HDs to the leading edge of cells, permitting its association with 
F-actin in motility structures and conferring a unique signaling potential (58, 85, 86, 135-
137).  Recent work from our laboratory has established an association between β4 and a 
“basal-like” subset of breast carcinomas, in which the expression of this integrin predicts 
decreased time to tumor recurrence and decreased patient survival (138).  β4 regulation of 
the expression and function of various downstream targets underlies the ability of this 
integrin to promote carcinoma progression (53, 63, 78, 79, 85, 98, 102).  miRNAs, 
however, represent a class of molecules that until recently had not yet been implicated in 
executing β4-mediated function.  Work from our laboratory identified a role for miR-29a 
in regulating invasion downstream of this integrin (139). 
miRNAs are non-coding single-stranded RNAs approximately 22 base pairs in 
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length that regulate gene expression through mRNA degradation or translational 
inhibition (108, 123).  In mammalian cells, miRNAs most commonly function by binding 
well-conserved imperfect complementary sequences in the 3’ UTR of their target mRNA 
to block translation (108, 123).  Our work is the only to date that suggests a role for 
integrins in the regulation of this small class of RNAs.  On the basis of our previous 
observations, as well as the growing role of miRNAs in tumorigenesis (140, 141) and 
their ability to regulate gene expression, we explored the effect of β4 integrin on global 
miRNA expression using a novel array approach termed qNPA.  The results obtained in 
this study demonstrate that β4 expression modulates families of miRNAs, and highlight a 
potential role for these miRNAs in executing β4-mediated cell motility. 
 
Results 
β4 status correlates with miRNA expression patterns 
Two breast carcinoma cell lines and a collection of invasive breast carcinomas 
with varying β4 status were examined to assay the effect of this integrin on miRNA 
expression.  MCF10CA1a cells were selected, because they are a highly aggressive breast 
carcinoma cell line in which β4 integrin is endogenously expressed.  Expression of the 
integrin was transiently depleted using siRNA (Fig. 2.1A).  MDA-MB-435 breast 
carcinoma cells, which express α6β1 endogenously but lack α6β4, were also chosen.  
Expression of the β4 subunit results in preferential heterodimerization of the α6 subunit 
with β4 (33, 142).  Stable subclones were generated expressing wild-type β4 (referred to 
as β4 transfectants); mock transfectants were also generated (Fig. 2.1B).  As the final 
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component of our analysis, a subset of breast carcinoma specimens was analyzed to 
substantiate cell line observations and establish a link between β4 and miRNAs in vivo.  
Specifically, twenty invasive ductal breast carcinomas were examined, half of which 
were positive for β4 expression, as established previously in our laboratory (138).  
To assay global miRNA expression, a novel microarray technology termed qNPA 
was utilized.  MCF10CA1a cells transfected with control siRNA or siRNA to β4 were 
collected 72 hours post-transfection and analyzed by qNPA.  Transient depletion of β4 in 
these cells altered the expression of 44 miRNAs (Table S2.1).  Two subclones of the 
MDA-MB-435/β4 transfectants (3A7 and 5B3) and two subclones of the MDA-MB-
435/mock transfectants (6D2 and 6D7) were examined for differential miRNA expression 
by qNPA.  Introduction of β4 into this system changed the expression of 50 miRNAs 
(Table S2.2).  Finally, ten β4 positive and ten β4 negative invasive breast carcinomas 
were also examined, and our analysis identified 74 miRNAs that were differentially 
expressed between tumor subsets (Table S2.3).  Statistical parameters of p-value < 0.05 
and a +/-1.2-fold change cut-off were applied to all array datasets.  The results from the 
three arrays are depicted in heat maps, in which the expression of each miRNA across 
samples was assigned a color value (Fig. 2.2).  The top 30 differentially regulated 
miRNAs from each array are presented in Table 2.1.  All miRNAs are normalized to the 
β4 null sample in each array, such that fold changes reflect the effect of the presence of 
β4 on any given miRNA.  miRNAs are ranked by increasing fold change.  Of particular 
interest, the major effect of β4 on miRNA expression appears to be repressive in nature. 
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β4 inversely correlates with the expression of select miRNA families 
 We next sought to correlate the results of the cell line and tumor analyses.  
miRNAs undergoing significant changes in expression were compared across datasets 
(Fig. 2.3A).  Two miRNAs, miR-100 and miR-1244, were altered in all three arrays.  
While miR-100 is a well-characterized miRNA widely expressed across vertebrates, very 
little is known about miR-1244 (143).  Upon closer examination of the data, we noted 
that several of the differentially regulated miRNAs belonged to common miRNA 
families.  A miRNA family is commonly defined as a group of miRNAs that shares the 
same seed sequence (nucleotides 2-7) and therefore largely overlapping target genes.  
Our observation prompted us to examine the idea that specific miRNA families might be 
influenced by β4 expression.  To address this hypothesis, all miRNA families represented 
in Fig. 2.3A were identified.  We then searched for miRNAs from each family across 
arrays.  A miRNA family was included in the analysis if two or more family members 
appeared in at least two of the three different array comparisons.  Conversely, miRNA 
families were excluded from consideration if the expression of any single family member 
was disconcordant with the expression profile of other family members within or across 
the three different arrays.  The results of our analysis identified seven families of 
miRNAs that changed in at least two of the arrays and two families of miRNAs whose 
expression was altered in all three of the arrays (Fig. 2.3B and Table 2.2).     
miRNA families target common β4-regulated genes involved in cell motility 
 miRNA families miR-25/32/92abc/363/363-3p/367 and miR-99ab/100 were 
identified by all three arrays as miRNA families whose expression are inversely 
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correlated with β4 status.  Specifically, miR-92a and miR-92b as well as miR-99a, miR-
99b, and miR-100 are downregulated in the presence of β4 across systems (Table 2.3).  
To explore the implications of this observation and to validate the physiological 
relevance of these miRNAs downstream of β4, we analyzed the mRNA data from a 
published Affymetrix GeneChip performed using the MDA-MB-435/β4 model system 
(76).  Specifically, we considered the possibility that these two families of miRNAs 
might be working in concert to upregulate the expression of genes important in executing 
β4 function.  To address this idea, we compared miR-92ab and miR-99ab/100 putative 
targets and generated a list of overlapping genes.  We then searched for these common 
genes within β4-regulated mRNAs.  Our analysis identified 54 β4-regulated genes that 
are predicted targets of both miR-92ab and miR-99ab/100 miRNA families, applying a p-
value < 0.05 and a 1.2-fold change cut-off (Table S2.4).  A list of the top 30 genes is 
presented in Table 2.4 and ranked in order of fold change.   
It was immediately apparent that several of these targets play critical roles in 
mediating cell motility, prompting us to speculate that these families of miRNAs 
specifically target genes involved in this biological process.  Applying the AmiGo gene 
ontology classification database v1.8 (144, 145), an enrichment was detected in genes 
associated with the accession term “cell motility” (GO:0048870) within this population 
of genes compared to all β4-upregulated genes using the hypergeometric probability (p = 
0.048).  Six genes were identified and include EPHA3, ABHD2, PTPN11, EFNB2, NF1, 
and CDK6.  Closer analysis uncovered additional genes that have been shown to promote 
cell motility despite having not been picked up by our gene ontology analysis.  These 
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genes include PIK3R3 (146), PPM1D (147), RASGRP3 (148, 149), ADAM19 (150), 
SORBS3 (151, 152), ITSN1 (153), MECP2 (154, 155), VLDLR (156), HIP1 (157), 
PAXIP1 (158), ITGA2 (159), ARFGEF1 (160, 161).   
Interestingly, several genes also play distinct roles in β4-mediated signaling 
cascades, including PIKR3, a regulatory subunit of the PI3K complex, as well as 
PTPN11, the gene encoding SHP-2.  Such observations are intriguing given that β4 
signals through the PI3K signaling cascade to increase cell migration and invasion (53).  
Furthermore, it was recently established that the tyrosine phosphatase SHP-2 binds to the 
cytoplasmic tail of β4 and plays a key role in activating downstream signaling events 
critical for cell invasion (69, 162).  These data provide compelling evidence that β4 
regulation of cell migration is executed in part by miR-92ab and miR-99ab/100 miRNA 
families through upregulation of genes both directly involved in cell migration as well as 
those important for preceding signal transduction events. 
β4-regulated mRNAs are enriched in putative targets of miRNA families 
 To extend our analysis, we next conducted gene set enrichment analyses to 
determine whether β4-regulated mRNAs were enriched for targets belonging to these two 
miRNA families.  A significant enrichment was detected (p = 0.028) for putative miR-
92ab targets in this population of genes; however, our analysis did not identify an 
enrichment for miR-99ab/100 predicted targets (Fig. 4A).  While this finding suggests 
that the miR-99ab/100 family likely does not target a large population of β4-regulated 
genes, it does not negate the possibility that these miRNAs function downstream of β4 to 
regulate the expression of select target genes involved in executing β4 function.  Earlier 
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work published from our laboratory has also established there to be no enrichment for 
predicted targets of miR-93, a miRNA selected as a negative control on the basis that it 
was expressed at robust levels in all samples from the qNPA arrays but did not change in 
response to expression of β4 (139).  As part of this analysis, lists of leading edge genes 
were generated, a compilation of mRNAs that contribute to the detected enrichment for 
miR-92ab (Table S2.5).     
Based on our findings, we were curious to determine whether other predicted 
targets for families of miRNAs were also enriched in this population of β4-regulated 
mRNAs.  To explore this idea using an unbiased approach, we employed the Broad 
Institute’s Molecular Signatures Database (MSigDB) C3:MIR Database, composed of 
gene sets sharing a 3'-UTR microRNA binding motif (163).  Interestingly, a comparison 
of this dataset to our β4-regulated mRNAs identified an enrichment for several of the 
miRNA families depicted in Fig. 2.3B and Table 2.2, including miR-
15abc/16/16abc/195/322/424/497/1907, miR-23abc/23b-3p, miR-27abc/27a-3p, and 
miR-30abcdef/30abe-5p/384-5p (Fig. 2.4B).  While these miRNA families were 
differentially regulated in only two of the three arrays, these data still provide compelling 
evidence that β4 status correlates with expression patterns of these miRNA families and 
suggests a role for them in mediating the expression of β4-regulated genes.  
 
Discussion 
We conclude from this study that integrin expression correlates with specific 
patterns of miRNA expression and that β4 integrin status effects the expression of 
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specific families of miRNAs.  Manipulation of β4 expression in two breast cancer cell 
lines provided in vitro model systems for analysis, while a collection of invasive breast 
carcinoma specimens established an in vivo link to the cell line data.  The novel qNPA 
array technology identified two miRNA families, miR-25/32/92abc/363/363-3p/367 and 
miR-99ab/100, as undergoing repression in the presence of β4 across all systems.  An 
analysis of published Affymetrix GeneChip data (76) identified 54 common putative 
targets of these two miRNA families within β4-regulated genes.  Many of these identified 
genes are established mediators of cell adhesion, cell motility, and signal transduction.  
Statistical analysis established that this population is enriched in genes involved in cell 
migration.  These data reveal previously unrecognized β4 targets, which could contribute 
to the ability of β4 to promote carcinoma progression.  Finally, gene set enrichment 
analysis detected an enrichment in predicted targets of several miRNA families, including 
miR-92ab, within β4-regulated genes, substantiating the physiological relevance of our 
findings with respect to the effect of β4 on the expression of distinct miRNA families.  
Although the fields of integrin and miRNA biology have been extensively linked 
to cancer initiation and progression, the connection between these two disciplines has 
remained elusive.  Our novel observation that a specific integrin correlates with miRNA 
expression has profound implications for development and disease, especially 
tumorigenesis.  Along these lines, tyrosine kinase receptors, such as EGFR, have also 
been shown to regulate miRNA expression (164).  Our data support the hypothesis that 
cells utilize this small class of RNAs to respond to external cues in their 
microenvironment, employing surface receptors like integrins as intermediates in the 
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delivery of key information.  An interesting observation that emerged from the results of 
the miRNA microarray analysis involves the predominantly repressive effect of β4 on 
global miRNA expression.  This is consistent with published data describing global 
downregulation of miRNA expression in cancers (165, 166).  Differential expression of 
the endogenous miRNA processing machinery represents a potential explanation for the 
repressive patterns of miRNA expression that we observed, as recent reports have 
highlighted the importance of miRNA processing genes in the regulation of miRNA 
biogenesis and function (167, 168).  We examined the expression of Dicer, Drosha, 
Ago1, Ago2, and TRPB2 mRNAs between the β4 and mock transfectants using 
Affymetrix GeneChip data but observed no change that could account for the 
downregulated pattern of miRNA expression (data not shown).   
Our observation that family members miR-92a and miR-92b are consistently 
downregulated in the presence β4 in our arrays is interesting considering the defined role 
of miR-92a as an “oncomir” (169).  miR-92a belongs to the miR-17-92 cluster, a group 
of six miRNAs generated from a single polycistronic transcript that includes miR-17, 
miR-18a, miR-19a, miR-20a, miR-19b, and miR-92a.  This cluster confers potent 
oncogenic potential and is overexpressed in a variety of cancers, often the result of 
genomic amplification (169).  These findings are seemingly at odds with our observation 
that miR-92a inversely correlates with the expression of β4, an integrin with a well-
established role in potentiating carcinoma cell migration, invasion, and survival.  Recent 
data, however, has identified a role for miRNAs from this family as tumor suppressors 
(170), highlighting the importance of cellular and molecular context in determining the 
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role of specific miRNAs in tumorigenesis.  Interestingly, an analysis of the arrays failed 
to identify consistent downregulation of other members from this miRNA cluster with the 
exception of miR-19b, which was repressed in two of the three arrays (data not shown).  
miR-92b, despite sharing the same seed sequence and common putative mRNA targets 
with miR-92a, is transcribed from an independent genomic locus and is less well 
characterized from a functional standpoint.  Its intergenic location near the THBS3 gene, 
which is known to share a common promoter with MTX1, prompted us to examine both 
thrombospondin 3 and metataxin 1 mRNA expression using our Affymetrix GeneChip 
data from the MDA-MB-435/β4 cells.  Conveniently, miR-92b was downregulated in this 
particular miRNA array; however, no detectable changes were observed in the expression 
of either thrombospondin 3 or metataxin 1 mRNA levels in this system (data not shown).  
This finding, along with the paucity of other downregulated miRNAs from the miR-17-
92 cluster, suggest changes in miR-92a and miR-92b expression are not mediated at a 
transcriptional level, rather the presence of this integrin likely affects the stability of these 
previously transcribed miRNAs.  Our hypothesis is intriguing in of light recent data 
linking miRNA decay to changes in cell adhesion (171), as well as the general notion that 
global miRNA expression is typically downregulated in cancer (165, 166).            
The role of miR-99a, miR-99b, and miR-100, the other miRNA family identified 
by our array, in tumorigenesis appears to be controversial.  However, downregulation of 
members of this miRNA family has been linked to breast carcinoma, hepatocellular 
carcinoma, prostate carcinoma, nasopharyngeal carcinoma, oral carcinomas, 
hepatoblastoma, and ovarian carcinoma (172-179).  All three miRNAs are transcribed 
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from independent genomic loci with clustered miRNAs.  miR-99a is co-transcribed with 
let-7c, miR-99b is co-transcribed with let-7e and miR-125a, and miR-100 is an intergenic 
miRNA co-transcribed with let-7a.  Again using the Affymetrix GeneChip data from the 
MDA-MB-435/β4 cells, we detected no change in the expression of genes surrounding 
the miR-100 cluster despite downregulation of miR-100 in this system (data not shown).  
However, we noted that all of the other co-transcribed clustered miRNAs were repressed 
across arrays (Table 2.2).  In fact, let-7a, let-7c, and let-7e belong to the let-
7/98/4458/4500 miRNA family and miR-125a belongs to the miR-125a-5p/125b-
5p/351/670/4319 miRNA family, both of which we identified to be downregulated by β4 
in two of the three arrays (Table 2.2).  Unlike miR-92a and miR-92b, these observations 
suggest a complex transcriptional mechanism that induces repression of miRNAs known 
to be genomically and functionally linked.  This observation provides compelling 
evidence that the relationship between β4 and the expression patterns of these miRNAs is 
biologically driven and highly conserved.  Furthermore, this observation diminishes our 
negative finding that the population of β4-regulated mRNAs does not contain an 
enrichment for miR-99ab/100 targets.  
Our observations that miR-92ab and miR-99ab/100 both target β4-regulated genes 
involved in cell motility and signal transduction suggests a novel miRNA-mediated 
mechanism by which β 4 promotes carcinoma cell migration and invasion.  Moreover, 
these data contribute to our understanding of β4 function in the context of signal 
transduction, implying that this integrin not only activates signaling cascades through 
phosphorylation events but upregulates absolute levels of molecules involved in these 
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complex processes.  Future studies aimed at exploring the mechanism of regulation of 
miR-25/32/92abc/363/363-3p/36 and miR-99ab/100 miRNA families in the presence of 
β4, as well as the role of putative targets in mediating cell motility downstream of this 
integrin, will provide further insight into the role of β4 function in promoting carcinoma 
progression. 
 
Materials and Methods
Cell Lines, Antibodies, and Reagents: MDA-MB-435 cells (180) were obtained from the 
Lombardi Cancer Center (Georgetown University, Washington, DC).  MCF10CA1a cells 
(181) were obtained from the Barbara Ann Karmanos Cancer Institute (Detroit, MI).  
MDA-MB-435 cell lines were maintained in low glucose DMEM medium (Gibco, 
Carlsbad, CA) supplemented with 10 mM HEPES, 5% fetal bovine serum, and 1% 
streptomycin and penicillin.  MCF10CA1a cells were maintained in DMEM/F12 1:1 
medium (Gibco, Carlsbad, CA) supplemented with 10 mM HEPES, 5% horse serum, and 
1% streptomycin and penicillin.  All cell lines were grown at 37°C in an incubator 
supplied with 5% CO2.  MDA-MB-435 mock transfectants (6D2 and 6D7 sublcones) and 
β4 transfectants (3A7 and 5B3 subclones) were generated and characterized as previously 
described (53).  The 505 antibody to β4 used for immunoblotting was produced by our 
laboratory as previously described (182). The antibody to tubulin (Sigma, St. Louis, MO) 
was also used for immunoblotting.  
siRNA Experiments: MCF10CA1a cells were transfected with 20 nM On-TARGETplus 
SMARTpool siRNA targeting β4 (Dharmacon) at 50% confluency using DharmaFECT 4 
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transfection reagent (Dharmacon).  A non-targeting siRNA pool (Dharmacon) was used 
as a control for these experiments.  At 72 h post-transfection, cells were harvested for 
protein as described below. 
Immunoblotting: Cells were solubilized on ice for 10 min in Triton X-100 lysis buffer 
(Boston Bioproducts, Ashland, MA) containing 50 mM Tris buffer, pH 7.4, 150 mM 
NaCl, 5mM EDTA, 1% Triton X-100, and protease inhibitors (Complete mini tab; Roche 
Applied Science, Indianapolis, IN) (Lysis Buffer A).  Nuclei were removed by 
centrifugation at 16,100 × g for 10 min.  Concentrations of total cell lysate were assayed 
by Bradford method.  Lysates (50 µg) were separated by electrophoresis through 10% 
SDS-PAGE and transferred to 0.2 µm nitrocellulose membranes (Bio-Rad, Hercules, 
CA).  Membranes were blocked in 5% nonfat milk in Tris-buffered saline/Tween 20 for 1 
h and blotted with the antibody to β4 (1:4,000) or tubulin (1:10,000) overnight at 4°C.  
Proteins were detected by enhanced chemiluminescence (Pierce, Rockford, IL) after 
incubation for 1 h with horseradish peroxidase-conjugated secondary antibodies. 
Tumor samples: A total of 20 cases of invasive ductal breast carcinomas were gross 
dissected by the Department of Pathology at the University of Massachusetts Medical 
School, Worcester, MA.  Ethics approval was not necessary because samples were 
discarded, anonymous, de-identified breast cancer specimens provided by the UMass 
Cancer Center Tissue Bank, which collects fresh tumor samples under University of 
Massachusetts Medical School IRB exemption (Docket # 12535, approved September 19, 
2011).  β4 expression was assessed as previously described (138).  Formalin-fixed 
paraffin-embedded sections of these tumors were generated for analysis by qNPA. 
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 qNPA™ miRNA Microarrays: 
Design: A novel qNPA based miRNA Microarray high throughput platform from High 
Throughput Genomics (HTG Molecular Diagnostics, Inc.; Tuscon, AZ) was used to study 
1050 mature miRNAs in human, rat, and mouse based upon the Sanger miRBase release 
9.1.  The qNPA based miRNA microarrays comprise DNA oligo capture probes that are 
synthesized directly on the slide surface (Roche NimbleGen, Madison, WI) which are 
complementary to, and capture, biotinylated miRNA-specific nuclease protection probes.  
Each microarray slide has 21 synthesized arrays, each representing all of the 1050 
miRNAs plus housekeeper genes, in separate wells in a design that mimics standard SBS 
96-well foot print using ArraySlide 24-4 Frame gasket (The Gel Company, San 
Francisco, CA), permitting 24 samples to be tested per slide.  
Sample preparation: For cell line analysis, cell lysates were prepared at a final 
concentration of 25,000 cells per reaction in 25 µl of Lysis Buffer (HTG).  For formalin-
fixed paraffin-embedded (FFPE) samples, FFPE tissue was scrapped off of slides into a 
clean eppendorf tube.  Tissues were lysed in 100 µl of Lysis Buffer covered with 600 µl 
of Denaturation oil at 95˚C for 15-20 min followed by digestion with 1:20 proteinase K 
(Ambion, Austin, TX).  Proteinase K digested FFPE lysate was distributed into 25 µl 
aliquots for each technical replicate and processed by regular qNPA procedure.  Three 
technical replicate samples were used for assaying miRNA expression. 
qNPA procedure and Quantification: qNPA was performed using 16-28bp 
complementary and 5` biotinylated Nuclease Protection Probes (NPPs) matching all the 
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unique human, rat, and mouse miRNA sequences from miRBase release 9.1.  Nuclease 
Protection Probes were added at a final concentration of 31.5 pM.  Samples were overlaid 
with 70µl of Denaturation Oil (HTG) and heated to 95˚C for 10-15 min followed by 16-
24 h hybridization in a 37˚C incubator to allow formation of NPP-miRNA duplexes.  S1 
nuclease was then added to degrade all non-hybridized NPPs, leaving behind NPP-
miRNA duplexes.  Base hydrolysis treatment of the NPP-miRNA complexes at 95oC 
followed, resulting in dissociation of the duplex, hydrolysis of the target miRNA, and 
free single-stranded NPPs present in amounts stoicheometric to those of miRNA present 
in the sample.  These free single-stranded NPPs were available for capture and detection 
on the array.  Base treatment was followed by neutralization using Neutralization solution 
(HTG) containing 1:200 proteinase K (Ambion).  The resulting qNPA lysate was then 
hybridized to the qNPA miRNA microarrays for 16-24 h in a 50˚C incubator for 
quantification of the NPPs.  After the NPP hybridization, qNPA Microarrays were 
washed rigorously with 1X wash buffer (HTG).  Microarrays were then hybridized with 
Avidin-peroxidase (1:600) and Nimblegen alignment oligos (500 pM) in Detection 
enzyme buffer (HTG) for 45 min at 37˚C.  Microarrays were washed followed by 
addition of TSA-Plus Cy3 reagent in amplification diluent (Perkin Elmer, Waltham, MA) 
for detection.  After a 3-min room temperature incubation, TSA-Plus Cy3 reaction was 
stopped by washing the arrays in wash buffer.  Finally, microarrays were spun dry and 
scanned at 5 µm resolution using a GenePix 4200AL microarray slide scanner (Molecular 
Devices, Sunnyvale, CA).  Probe intensities were extracted from TIFF images using 
NimbleScan 2.5 software (Roche NimbleGen) for further analysis.  
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Statistical Analysis: Microarrays for each sample were performed in triplicate (technical 
replicates).  For each array, human miRNA raw expression values were extracted, 
converted to log base 2, and intra-array miRNA replicates (spot replicates) averaged.  
Arrays were then normalized to one another using the median miRNA expression value 
on each array.  BRB-ArrayTools v4.1.0 was used for all analyses (183).  Differentially 
expressed miRNAs were selected using a random variance t-test p value less than 0.05 
and an absolute fold change greater than 1.2.  miRNAs were eliminated from 
consideration if the average value of both β4 positive and β4 negative samples on a single 
microarray fell below the average background level detected on that particular 
microarray.  Estimates of the false discovery rate (FDR) were made using the method of 
Benjamini and Hochberg (184).  Heat map false-coloring of Figure 2.2 was applied using 
Matrix2png (http://www.chibi.ubc.ca/matrix2png) (185).  miRNA values in each row 
were normalized to have a mean of zero and a variance of one.  Coloring was applied 
linearly to normalized values between the 2nd and 98th percentile, while saturating color 
was applied below the 2nd percentile or above the 98th percentile.  Gene order on the y-
axis is identical to the gene order in Tables S2.1-S2.3. 
Lists of predicted targets of miRNAs used for analyses depicted in Tables 2.4 and 
2.5 and gene set enrichment analyses depicted in Fig. 2.4 were obtained from publicly 
available algorithms TargetScan Human Release 5.1 (http://www.targetscan.org/) and 
miRanda August 2010 Release (http://www.microrna.org/).  Genes involved in cell 
migration (GO:0016477) were identified using the AmiGo gene ontology classification 
database v1.8 (144, 145) available through the Gene Ontology project 
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(www.geneontology.org).  The hypergeometric probability (www.stattrek.com) was 
measured using a population size of 1487 (upregulated β4 mRNAs), sample size of 54 
(common miR-92ab and miR-99ab/100 targets among β4-regulated mRNAs), successes 
in population of 83 (cell motility genes identified in upregulated β4 mRNAs), and 
successes in sample of 6 (cell motility genes identified in common miR-92ab and miR-
99ab/100 targets among β4-regulated mRNAs).  For miRNA gene set enrichment 
analysis in Fig. 2.4, mRNA expression data generated by Chen et. al. (76) was 
downloaded from the NCBI Gene Expression Omnibus (GEO), series number 
GSE11466.  Affymetrix CEL files were processed with the robust multi-chip average 
(RMA) algorithm (186) using BRB-ArrayTools.  Using total context score, the top 500 
conserved targets for miR-92ab or miR-99ab/100 were compiled into gene set lists.  Log 
base 2 mRNA data was loaded into the Broad Institute’s Gene Set Enrichment Analysis 
(GSEA) software v2.06 (163, 187).  β4 phenotype was compared to mock phenotype by 
first collapsing the dataset to gene symbols and then using a weighted, difference of 
classes metric for ranking genes.  Gene set permutations were performed to generate 
nominal p-values for each miRNA target gene set list.  
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Table 2.1.  Effect of β4 expression on miRNA levels
miRNA Fold Change (β4/Mock) miRNA
Fold Change 
(siCtrl/siβ4) miRNA
Fold Change 
(β4+/β4-)
hsa-miR-29a -5.56 hsa-miR-187 -3.04 hsa-miR-92b -3.02
hsa-miR-886-5p -5.26 hsa-miR-574-5p -2.19 hsa-miR-145 -2.89
hsa-miR-29b -5.26 hsa-miR-146a -2.00 hsa-miR-191 -2.79
hsa-miR-125b -3.03 hsa-miR-216b -1.95 hsa-miR-193b -2.67
hsa-miR-100 -2.94 hsa-miR-127-5p -1.95 hsa-miR-423-3p -2.52
hsa-miR-342-3p -2.70 hsa-miR-516b -1.88 hsa-miR-342-3p -2.40
hsa-miR-22 -2.33 hsa-miR-190 -1.85 hsa-miR-24 -2.37
hsa-miR-27a -2.27 hsa-miR-616 -1.63 hsa-miR-99b -2.37
hsa-miR-23a -2.17 hsa-miR-100 -1.60 hsa-miR-574-3p -2.34
hsa-miR-130a -2.04 hsa-miR-1233 -1.59 hsa-miR-16 -2.30
hsa-miR-15b -2.00 hsa-miR-421 1.61 hsa-miR-27a -2.27
hsa-miR-16 -1.96 hsa-miR-330-3p 1.61 hsa-miR-320a -2.23
hsa-miR-182 -1.92 hsa-miR-105 1.64 hsa-miR-103 -2.22
hsa-miR-24 -1.92 hsa-miR-33b 1.65 hsa-let-7a -2.18
hsa-miR-222 -1.92 hsa-miR-218 1.68 hsa-miR-320b -2.15
hsa-let-7f -1.82 hsa-miR-18a 1.73 hsa-let-7f -2.13
hsa-miR-708 -1.72 hsa-miR-422a 1.75 hsa-miR-199a-5p -2.13
hsa-miR-29c -1.69 hsa-miR-708 1.77 hsa-let-7b -2.03
hsa-miR-92b -1.67 hsa-miR-1284 1.79 hsa-miR-149 -2.02
hsa-miR-185 -1.67 hsa-miR-559 1.81 hsa-miR-1291 -2.01
hsa-miR-30c -1.61 hsa-miR-33a 1.88 hsa-miR-92a -2.00
hsa-miR-1244 -1.61 hsa-miR-331-5p 1.91 hsa-miR-214 -1.96
hsa-miR-151-5p -1.59 hsa-miR-29b 1.92 hsa-miR-93 -1.91
hsa-miR-1260 -1.56 hsa-miR-632 1.93 hsa-miR-143 -1.90
hsa-miR-20b -1.54 hsa-miR-29c 1.96 hsa-miR-1259 -1.88
hsa-miR-30b -1.52 hsa-miR-375 1.96 hsa-miR-193a-5p -1.86
hsa-miR-606 -1.47 hsa-miR-301b 1.97 hsa-miR-200c -1.83
hsa-let-7b -1.47 hsa-miR-891b 2.16 hsa-miR-107 -1.81
hsa-miR-1201 -1.47 hsa-miR-936 2.35 hsa-miR-195 -1.81
hsa-miR-768-3p 1.59 hsa-miR-622 2.76 hsa-miR-650 1.79
MDA-MB-435 MCF10CA1a Tumors
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Table 2.2.  Effect of β4 expression on miRNA families
miRNA Family
Effect of β4 
on 
Expression
MDA-MB-435 MCF10CA1a Tumors
let-7/98/4458/4500  let-7a let-7a
let-7b let-7b
let-7e let-7c
let-7f let-7e
let-7f
miR-15abc/16/16abc/195/322/424/497/1907  miR-15a miR-15a
miR-15b miR-15b
miR-16 miR-16
miR-195
miR-23abc/23b-3p  miR-23a miR-23a
miR-23b miR-23b
miR-27abc/27a-3p  miR-27a miR-27a
miR-27b
miR-30abcdef/30abe-5p/384-5p  miR-30a miR-30a
miR-30b miR-30c
miR-30c miR-30d
miR-25/32/92abc/363/363-3p/367  miR-92b miR-92a miR-92a
miR-92b
miR-99ab/100  miR-100 miR-100 miR-99a
miR-99b
miR-100
miR-125a-5p/125b-5p/351/670/4319  miR-125b miR-125a-5p
miR-125b
miR-221/222/222ab/1928  miR-222 miR-221
miR-222
Differentially Expressed miRNA Family 
Members
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Table 2.3.  Effect of β4 expression on miR-92ab and miR-99ab/100 family members  
miRNA p-value FDR1
siCtrl Average 
Intensity
siβ4 Average 
Intensity
Fold Change 
(siCtrl/siβ4)
hsa-miR-92a 4.87E-02 6.07E-01 14599 21407 -1.47
hsa-miR-100 1.75E-02 5.30E-01 15424 24711 -1.60
miRNA p-value FDR Average β4 Intensity
Average Mock 
Intensity
Fold Change 
(β4/Mock)
hsa-miR-92b 4.0E-06 3.5E-04 2837 4700 -1.67
hsa-miR-100 5.0E-07 5.9E-05 2625 7732 -2.94
miRNA p-value FDR Average β4+ Intensity
Average β4- 
Intensity
Fold Change 
(β4+/β4-)
hsa-miR-92a 1.16E-02 8.31E-02 3498 6989 -2.00
hsa-miR-92b 4.50E-06 1.06E-03 1125 3400 -3.02
hsa-miR-99a 2.72E-02 1.42E-01 393 551 -1.40
hsa-miR-99b 4.65E-04 1.22E-02 926 2190 -2.37
hsa-miR-100 1.74E-02 1.09E-01 272 338 -1.24
1 False Discovery Rate
MCF10CA1a Array
MDA-MB-435 Array
Tumor Array
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Table 2.4.  Predicted targets of miR-92ab and miR-99ab/100 families among β4-regulated genes
Gene ID  p-value FDR1
Average β4 
Intensity
Average Mock 
Intensity
Fold Change 
(β4/Mock)
EPHA3 4.79E-04 1.56E-02 265 104 2.54
GOLGA8A 7.60E-06 1.54E-03 148 65 2.28
ABHD2 4.79E-05 4.13E-03 168 75 2.22
SGCD 7.74E-03 7.84E-02 259 124 2.09
DCP2 3.05E-04 1.19E-02 149 84 1.78
RMND5A 1.37E-03 2.79E-02 108 61 1.76
WWP2 3.37E-03 4.75E-02 377 220 1.71
AMMECR1 1.55E-04 7.88E-03 125 73 1.70
KLHDC3 3.07E-05 3.27E-03 759 461 1.65
PTPN11 1.96E-04 9.26E-03 335 210 1.60
ZC3HAV1 9.30E-03 8.74E-02 168 108 1.56
ZFP106 3.67E-02 2.01E-01 473 310 1.52
CTDSPL 6.60E-05 4.94E-03 419 276 1.51
BAT2L2 2.94E-03 4.40E-02 137 92 1.49
PIK3R3 3.33E-03 4.72E-02 125 84 1.49
ZNF652 6.64E-04 1.88E-02 48 33 1.47
EFNB2 8.31E-03 8.19E-02 70 48 1.46
PPM1D 7.34E-05 5.13E-03 41 28 1.46
SOBP 9.55E-03 8.89E-02 40 28 1.46
NKTR 2.50E-03 4.01E-02 84 59 1.43
FOXO3 2.59E-03 4.11E-02 262 184 1.42
ZNF331 7.34E-05 5.13E-03 64 45 1.42
PKNOX1 1.47E-04 7.69E-03 68 49 1.40
RASGRP3 7.45E-03 7.64E-02 35 25 1.40
ADAM19 1.61E-03 3.08E-02 200 146 1.37
GNS 1.64E-03 3.11E-02 147 107 1.37
MFHAS1 5.10E-03 6.04E-02 213 155 1.37
WDFY3 4.25E-02 2.19E-01 60 43 1.37
WDR37 1.01E-02 9.20E-02 199 145 1.37
SORBS3 4.62E-02 2.29E-01 289 215 1.34
1 False Discovery Rate
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Figure 2.1.  β4 expression in breast carcinoma cell lines.  A, Expression of β4 in total 
cell extract (50 µg) following transient knockdown of β4 at 72 hours post-transfection in 
MCF10CA1a cells.  B, Expression of β4 in total cell extract (50 µg) in MDA-MB-435/β4 
and mock transfectants.  
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Figure 2.2.  β4 correlates with miRNA expression patterns.  A, qNPA microarray was 
performed in triplicate on MCF10CA1a siCtrl cells and MCF10CA1a siβ4 cells at 72 
hours post-transfection.  The heat map depicts the 44 miRNAs undergoing a statistically 
significant change in expression following transient depletion of β4 subunit in this 
system.  B, qNPA microarray was performed in triplicate on two subclones of the MDA-
MB-435/β4 transfectants (3A7 and 5B3), and two subclones of the MDA-MB-435/mock 
transfectants (6D2 and 6D7).  The heat map depicts the 50 miRNAs undergoing a 
statistically significant change in expression following introduction of the β4 subunit into 
this system.  C, qNPA microarray was performed in triplicate on ten β4 positive and ten 
β4 negative invasive breast carcinomas.  The heat map depicts the 74 miRNAs 
differentially expressed between tumor subsets.  For all array analyses, a p-value < 0.05 
and a +/-1.2-fold change cut-off was applied.  Color was assigned to each miRNA based 
on relative expression across samples. 
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Figure 2.3.  β4 inversely correlates with the expression of select miRNA families.  A, 
Venn diagram of overlapping miRNAs that undergo differential expression in response to 
β4 across all three arrays.  B, Venn diagram of overlapping miRNA families that undergo 
differential expression in response to β4 across all three arrays.
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Figure 2.4.  β4-regulated mRNAs are enriched in putative targets of miRNA 
families.  GeneChip derived mRNA levels were ranked from the most upregulated in β4 
transfected cells to the most downregulated (x-axis, 1 to 12,300, respectively).  Red 
shading indicates mRNA is upregulated in β4 transfectants, while blue shading indicates 
mRNA is downregulated.  Each vertical black line represents a miRNA target.  The left-
to-right position of each black line indicates the relative position of the predicted target 
within the rank ordered mRNA list.  A, miR-92ab predicted target gene are enriched 
among mRNAs up-regulated in the β4 transfectants, as illustrated by the increasing 
number of black lines on the left side of each graphic and the positive running enrichment 
scores (ES) marked by the red lines (p = 0.028).  No enrichment was detected for and 
miR-99ab/100.  B, miR-15abc/16/16abc/195/322/424/497/1907 (p = 0.039), miR-
23abc/23b-3p (p = 0.034), miR-27abc/27a-3p ( p = 0.003), and miR-30abcdef/30abe-
5p/384-5p (p = 0.0) predicted target genes are enriched among mRNAs up-regulated in 
the β4 transfectants. 
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Table S2.1.  MCF10CA1a microarray
miRNA p-value FDR siCtrl Average Intensity
siβ4 Average 
Intensity
Fold Change 
(siCtrl/siβ4)
hsa-miR-187 1.16E-04 4.00E-02 224 682 -3.04
hsa-miR-574-5p 4.88E-04 1.12E-01 3313 7249 -2.19
hsa-miR-146a 6.25E-03 3.58E-01 5253 10509 -2.00
hsa-miR-216b 2.62E-02 5.30E-01 85 165 -1.95
hsa-miR-127-5p 6.14E-03 3.58E-01 83 162 -1.95
hsa-miR-516b 1.88E-02 5.30E-01 88 165 -1.88
hsa-miR-190 1.53E-02 5.25E-01 2193 4055 -1.85
hsa-miR-616 1.51E-02 5.25E-01 88 144 -1.63
hsa-miR-100 1.75E-02 5.30E-01 15424 24711 -1.60
hsa-miR-1233 2.94E-02 5.69E-01 2034 3227 -1.59
hsa-miR-222 2.20E-02 5.30E-01 16389 25755 -1.57
hsa-miR-1275 3.12E-02 5.69E-01 122 188 -1.55
hsa-miR-637 4.02E-02 5.89E-01 115 177 -1.54
hsa-miR-221 2.58E-02 5.30E-01 14804 22546 -1.52
hsa-miR-31 3.03E-02 5.69E-01 13659 20667 -1.51
hsa-miR-768-5p 3.72E-02 5.89E-01 19319 28784 -1.49
hsa-miR-296-5p 4.98E-02 6.07E-01 11986 17752 -1.48
hsa-miR-1207-5p 4.47E-02 6.07E-01 11006 16274 -1.48
hsa-miR-1244 3.95E-02 5.89E-01 15632 23057 -1.47
hsa-miR-92a 4.87E-02 6.07E-01 14599 21407 -1.47
hsa-miR-194 3.83E-02 5.89E-01 169 113 1.50
hsa-miR-1248 3.96E-02 5.89E-01 7343 4843 1.52
hsa-miR-548c-5p 2.42E-02 5.30E-01 152 98 1.55
hsa-miR-609 3.33E-02 5.88E-01 176 112 1.56
hsa-miR-421 2.42E-02 5.30E-01 486 301 1.61
hsa-miR-330-3p 2.60E-02 5.30E-01 892 553 1.61
hsa-miR-105 3.50E-02 5.89E-01 164 100 1.64
hsa-miR-33b 2.46E-02 5.30E-01 146 88 1.65
hsa-miR-218 1.52E-02 5.25E-01 201 120 1.68
hsa-miR-18a 1.76E-02 5.30E-01 452 261 1.73
hsa-miR-422a 1.17E-02 5.25E-01 296 170 1.75
hsa-miR-708 7.18E-03 3.80E-01 1215 688 1.77
hsa-miR-1284 2.22E-02 5.30E-01 183 103 1.79
hsa-miR-559 9.02E-03 4.43E-01 383 211 1.81
hsa-miR-33a 1.92E-02 5.30E-01 169 89 1.88
hsa-miR-331-5p 3.46E-03 3.36E-01 211 111 1.91
hsa-miR-29b 3.68E-03 3.36E-01 7537 3932 1.92
hsa-miR-632 1.40E-02 5.25E-01 183 95 1.93
hsa-miR-29c 1.24E-02 5.25E-01 409 209 1.96
hsa-miR-375 3.99E-03 3.36E-01 598 305 1.96
hsa-miR-301b 1.80E-03 2.48E-01 183 93 1.97
hsa-miR-891b 4.88E-03 3.36E-01 197 91 2.16
hsa-miR-936 1.43E-03 2.45E-01 483 206 2.35
hsa-miR-622 3.21E-05 2.21E-02 2322 843 2.76
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Table S2.2.  MDA-MB-435 microarray
miRNA p-value FDR Average β4 Intensity
Average Mock 
Intensity
Fold Change 
(β4/Mock)
hsa-miR-29a <1.0E-07 <1.0E-07 2410 13323 -5.56
hsa-miR-886-5p <1.0E-07 <1.0E-07 201 1074 -5.26
hsa-miR-29b <1.0E-07 <1.0E-07 715 3696 -5.26
hsa-miR-125b 1.0E-07 1.4E-05 722 2187 -3.03
hsa-miR-100 5.0E-07 5.9E-05 2625 7732 -2.94
hsa-miR-342-3p 3.7E-06 3.5E-04 278 749 -2.70
hsa-miR-22 6.5E-06 4.6E-04 424 979 -2.33
hsa-miR-27a 5.5E-05 2.4E-03 3808 8560 -2.27
hsa-miR-23a 1.7E-04 5.7E-03 2331 5060 -2.17
hsa-miR-130a 1.0E-07 1.4E-05 167 342 -2.04
hsa-miR-15b 2.9E-05 1.5E-03 882 1762 -2.00
hsa-miR-16 3.4E-04 1.1E-02 8831 17398 -1.96
hsa-miR-182 2.0E-05 1.1E-03 369 703 -1.92
hsa-miR-24 1.2E-04 4.3E-03 3756 7173 -1.92
hsa-miR-222 8.2E-04 2.2E-02 1163 2254 -1.92
hsa-let-7f 1.9E-03 4.2E-02 4985 9048 -1.82
hsa-miR-708 3.5E-05 1.7E-03 160 277 -1.72
hsa-miR-29c 1.4E-05 8.0E-04 222 380 -1.69
hsa-miR-92b 4.0E-06 3.5E-04 2837 4700 -1.67
hsa-miR-185 1.2E-03 2.9E-02 294 493 -1.67
hsa-miR-30c 2.7E-03 5.6E-02 556 899 -1.61
hsa-miR-1244 8.0E-03 1.3E-01 1375 2226 -1.61
hsa-miR-151-5p 3.6E-03 6.8E-02 304 483 -1.59
hsa-miR-1260 8.6E-05 3.4E-03 452 708 -1.56
hsa-miR-20b 6.0E-04 1.8E-02 301 462 -1.54
hsa-miR-30b 8.7E-03 1.3E-01 304 461 -1.52
hsa-miR-606 7.8E-03 1.3E-01 603 887 -1.47
hsa-let-7b 8.3E-03 1.3E-01 329 484 -1.47
hsa-miR-1201 9.8E-03 1.4E-01 314 459 -1.47
hsa-miR-23b 1.4E-03 3.5E-02 356 519 -1.45
hsa-miR-574-3p 6.8E-04 1.9E-02 1009 1433 -1.43
hsa-let-7a 3.3E-02 2.9E-01 365 520 -1.43
hsa-miR-765 2.5E-03 5.2E-02 214 296 -1.39
hsa-miR-30a 2.1E-02 2.2E-01 327 454 -1.39
hsa-miR-181a 3.4E-02 3.0E-01 1756 2441 -1.39
hsa-miR-345 1.9E-03 4.2E-02 289 396 -1.37
hsa-miR-663b 9.1E-03 1.4E-01 6578 9069 -1.37
hsa-miR-486-5p 2.0E-02 2.2E-01 468 646 -1.37
hsa-miR-19b 2.1E-02 2.2E-01 1675 2304 -1.37
hsa-miR-720 1.7E-02 2.0E-01 1149 1529 -1.33
hsa-miR-1296 2.4E-02 2.3E-01 187 250 -1.33
hsa-miR-15a 1.3E-02 1.7E-01 308 403 -1.32
hsa-miR-27b 1.8E-02 2.1E-01 278 359 -1.30
hsa-let-7e 8.5E-03 1.3E-01 217 276 -1.28
hsa-miR-1234 2.2E-02 2.2E-01 215 275 -1.28
hsa-miR-885-3p 1.3E-02 1.7E-01 225 286 -1.27
57
hsa-miR-486-3p 2.0E-02 2.2E-01 336 426 -1.27
hsa-miR-320d 2.0E-02 2.2E-01 268 208 1.28
hsa-miR-320a 2.8E-02 2.6E-01 2036 1503 1.36
hsa-miR-768-3p 1.0E-05 6.6E-04 6480 4072 1.59
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Table S2.3.  Tumor microarray
miRNA p-value FDR
Average β4 
Positive 
Intensity
Average β4 
Negative 
Intensity
Fold Change 
(β4+/β4-)
hsa-miR-92b 4.50E-06 1.06E-03 1125 3400 -3.02
hsa-miR-145 1.47E-05 1.48E-03 2472 7138 -2.89
hsa-miR-191 1.40E-06 9.90E-04 4391 12237 -2.79
hsa-miR-193b 2.32E-04 9.10E-03 2769 7384 -2.67
hsa-miR-423-3p 9.70E-06 1.14E-03 903 2279 -2.52
hsa-miR-342-3p 3.38E-03 3.98E-02 4442 10662 -2.40
hsa-miR-24 1.00E-03 2.02E-02 2570 6103 -2.37
hsa-miR-99b 4.65E-04 1.22E-02 926 2190 -2.37
hsa-miR-574-3p 2.76E-04 9.31E-03 719 1683 -2.34
hsa-miR-16 5.31E-04 1.29E-02 3219 7419 -2.30
hsa-miR-27a 4.53E-04 1.22E-02 1086 2469 -2.27
hsa-miR-320a 9.98E-05 5.43E-03 1361 3034 -2.23
hsa-miR-103 2.06E-04 8.55E-03 569 1265 -2.22
hsa-let-7a 2.06E-05 1.82E-03 439 956 -2.18
hsa-miR-320b 7.53E-05 4.84E-03 792 1698 -2.15
hsa-let-7f 1.48E-04 6.96E-03 5451 11590 -2.13
hsa-miR-199a-5p 2.76E-04 9.31E-03 429 915 -2.13
hsa-let-7b 4.60E-05 3.25E-03 423 859 -2.03
hsa-miR-149 2.03E-03 2.86E-02 262 529 -2.02
hsa-miR-1291 2.64E-04 9.31E-03 7451 14960 -2.01
hsa-miR-92a 1.16E-02 8.31E-02 3498 6989 -2.00
hsa-miR-214 2.75E-03 3.41E-02 6456 12668 -1.96
hsa-miR-93 3.50E-03 4.06E-02 578 1107 -1.91
hsa-miR-143 9.30E-06 1.14E-03 325 617 -1.90
hsa-miR-1259 5.50E-03 5.47E-02 673 1266 -1.88
hsa-miR-193a-5p 8.84E-05 5.21E-03 369 687 -1.86
hsa-miR-200c 1.42E-03 2.29E-02 433 791 -1.83
hsa-miR-107 1.31E-03 2.29E-02 435 787 -1.81
hsa-miR-195 2.80E-06 9.90E-04 318 574 -1.81
hsa-miR-484 1.30E-02 8.75E-02 1228 2170 -1.77
hsa-miR-423-5p 1.50E-03 2.30E-02 847 1424 -1.68
hsa-miR-23a 1.27E-02 8.72E-02 714 1191 -1.67
hsa-miR-125a-5p 2.72E-03 3.41E-02 348 569 -1.64
hsa-miR-22 1.30E-03 2.29E-02 345 550 -1.59
hsa-miR-30d 2.73E-03 3.41E-02 320 506 -1.58
hsa-miR-620 6.19E-03 5.76E-02 419 663 -1.58
hsa-miR-675 2.42E-02 1.37E-01 325 511 -1.57
hsa-miR-1248 1.22E-02 8.52E-02 399 623 -1.56
hsa-miR-125b 6.15E-03 5.76E-02 443 686 -1.55
hsa-miR-197 2.76E-02 1.42E-01 573 887 -1.55
hsa-miR-606 8.69E-03 7.23E-02 343 523 -1.53
hsa-miR-532-3p 3.71E-02 1.69E-01 460 700 -1.52
hsa-miR-1307 2.91E-02 1.43E-01 507 763 -1.51
hsa-miR-492 6.40E-04 1.46E-02 236 351 -1.49
59
hsa-miR-205 3.55E-02 1.65E-01 293 433 -1.48
hsa-miR-34a 3.34E-03 3.98E-02 353 519 -1.47
hsa-miR-19b 4.75E-02 1.90E-01 308 446 -1.45
hsa-miR-29a 1.10E-02 8.23E-02 371 537 -1.45
hsa-miR-1244 3.89E-02 1.72E-01 385 550 -1.43
hsa-miR-187 1.64E-03 2.47E-02 240 340 -1.42
hsa-miR-425 1.36E-03 2.29E-02 247 351 -1.42
hsa-miR-99a 2.72E-02 1.42E-01 393 551 -1.40
hsa-miR-744 3.93E-03 4.14E-02 283 390 -1.38
hsa-miR-151-5p 1.71E-02 1.08E-01 268 368 -1.37
hsa-miR-31 2.16E-03 2.93E-02 231 316 -1.37
hsa-miR-15b 1.19E-02 8.39E-02 251 340 -1.36
hsa-miR-127-3p 4.43E-02 1.84E-01 339 455 -1.34
hsa-miR-30a 3.22E-04 1.03E-02 220 287 -1.31
hsa-miR-324-5p 9.14E-03 7.43E-02 277 363 -1.31
hsa-let-7c 1.45E-04 6.96E-03 227 295 -1.30
hsa-miR-23b 3.32E-02 1.58E-01 305 392 -1.29
hsa-miR-26a 1.90E-02 1.15E-01 285 367 -1.29
hsa-miR-30c 2.11E-03 2.92E-02 219 282 -1.29
hsa-miR-320c 2.30E-03 3.07E-02 270 342 -1.27
hsa-let-7e 2.34E-02 1.34E-01 265 327 -1.24
hsa-miR-100 1.74E-02 1.09E-01 272 338 -1.24
hsa-miR-15a 6.32E-03 5.80E-02 229 279 -1.22
hsa-miR-340 1.16E-02 8.31E-02 214 258 -1.20
hsa-miR-661 2.76E-02 1.42E-01 256 210 1.22
hsa-miR-615-5p 1.18E-03 2.19E-02 354 288 1.23
hsa-miR-1280 1.11E-02 8.23E-02 37962 27554 1.37
hsa-miR-150 4.86E-02 1.90E-01 433 309 1.41
hsa-miR-346 1.35E-03 2.29E-02 302 212 1.43
hsa-miR-650 2.56E-02 1.41E-01 910 511 1.79
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Table S2.4.  Overlapping miR-92ab and miR-99ab/100 β4-regulated mRNAs
Gene ID  p-value FDR Average β4 Intensity
Average Mock 
Intensity
Fold Change 
(β4/Mock)
EPHA3 4.79E-04 1.56E-02 265 104 2.54
GOLGA8A 7.60E-06 1.54E-03 148 65 2.28
ABHD2 4.79E-05 4.13E-03 168 75 2.22
SGCD 7.74E-03 7.84E-02 259 124 2.09
DCP2 3.05E-04 1.19E-02 149 84 1.78
RMND5A 1.37E-03 2.79E-02 108 61 1.76
WWP2 3.37E-03 4.75E-02 377 220 1.71
AMMECR1 1.55E-04 7.88E-03 125 73 1.70
KLHDC3 3.07E-05 3.27E-03 759 461 1.65
PTPN11 1.96E-04 9.26E-03 335 210 1.60
ZC3HAV1 9.30E-03 8.74E-02 168 108 1.56
ZFP106 3.67E-02 2.01E-01 473 310 1.52
CTDSPL 6.60E-05 4.94E-03 419 276 1.51
BAT2L2 2.94E-03 4.40E-02 137 92 1.49
PIK3R3 3.33E-03 4.72E-02 125 84 1.49
ZNF652 6.64E-04 1.88E-02 48 33 1.47
EFNB2 8.31E-03 8.19E-02 70 48 1.46
PPM1D 7.34E-05 5.13E-03 41 28 1.46
SOBP 9.55E-03 8.89E-02 40 28 1.46
NKTR 2.50E-03 4.01E-02 84 59 1.43
FOXO3 2.59E-03 4.11E-02 262 184 1.42
ZNF331 7.34E-05 5.13E-03 64 45 1.42
PKNOX1 1.47E-04 7.69E-03 68 49 1.40
RASGRP3 7.45E-03 7.64E-02 35 25 1.40
ADAM19 1.61E-03 3.08E-02 200 146 1.37
GNS 1.64E-03 3.11E-02 147 107 1.37
MFHAS1 5.10E-03 6.04E-02 213 155 1.37
WDFY3 4.25E-02 2.19E-01 60 43 1.37
WDR37 1.01E-02 9.20E-02 199 145 1.37
SORBS3 4.62E-02 2.29E-01 289 215 1.34
ITSN1 1.85E-03 3.32E-02 23 18 1.33
MECP2 9.82E-04 2.32E-02 198 149 1.33
VLDLR 2.81E-02 1.70E-01 80 60 1.33
HIP1 2.93E-02 1.75E-01 61 46 1.32
NIPBL 5.85E-03 6.58E-02 68 52 1.32
HLCS 3.32E-03 4.72E-02 132 101 1.31
PAXIP1 1.36E-03 2.79E-02 189 144 1.31
RNMT 3.71E-03 5.04E-02 196 150 1.31
SGSH 4.05E-03 5.29E-02 498 383 1.30
FNTA 3.31E-03 4.72E-02 290 225 1.29
MTMR1 2.35E-02 1.53E-01 60 47 1.29
SR140 2.04E-02 1.40E-01 88 68 1.29
FBXL18 2.08E-03 3.60E-02 142 111 1.28
ITGA2 9.05E-03 8.60E-02 73 57 1.28
CASK 1.03E-02 9.31E-02 161 127 1.27
AP1AR 1.16E-02 1.00E-01 92 74 1.25
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ARFGEF1 4.76E-02 2.33E-01 188 150 1.25
HN1L 1.59E-03 3.07E-02 1011 811 1.25
MTF1 2.54E-02 1.60E-01 142 113 1.25
S100PBP 1.94E-02 1.36E-01 89 71 1.25
UBE2I 9.20E-03 8.69E-02 1253 1003 1.25
DYRK1A 8.43E-03 8.24E-02 541 441 1.23
NF1 7.42E-03 7.63E-02 128 104 1.23
CDK6 4.05E-02 2.13E-01 96 79 1.22
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Table S2.5.  miR-92ab leading edge genes 
Gene 
Symbol Gene Title
Rank in 
Gene List1
Rank Metric 
Score2
Running 
ES3
SOX4 SRY (sex determining region Y)-box 4 10 2.005 0.016
HAPLN1 hyaluronan and proteoglycan link protein 1 37 1.253 0.024
FRYL furry homolog-like (Drosophila) 88 0.975 0.028
TMEM50B transmembrane protein 50B 93 0.951 0.036
AXL AXL receptor tyrosine kinase 124 0.855 0.040
TOB1 transducer of ERBB2, 1 129 0.843 0.047
DCP2 DCP2 decapping enzyme homolog (S. cerevisiae) 134 0.829 0.054
SEMA3A sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A 138 0.813 0.060
DMXL1 Dmx-like 1 143 0.809 0.066
COL1A2 collagen, type I, alpha 2 153 0.795 0.072
TMF1 TATA element modulatory factor 1 163 0.778 0.078
WWP2 WW domain containing E3 ubiquitin protein ligase 2 164 0.777 0.084
CCNE2 cyclin E2 180 0.751 0.089
ITM2B integral membrane protein 2B 183 0.749 0.095
KIF3B kinesin family member 3B 198 0.722 0.100
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 215 0.702 0.105
CHD9 chromodomain helicase DNA binding protein 9 219 0.699 0.110
FMR1 fragile X mental retardation 1 228 0.687 0.115
ASPH aspartate beta-hydroxylase 252 0.668 0.119
MTMR9 myotubularin related protein 9 261 0.662 0.124
GRAMD3 GRAM domain containing 3 277 0.649 0.128
MMP16 matrix metallopeptidase 16 (membrane-inserted) 278 0.649 0.133
ICK intestinal cell (MAK-like) kinase 281 0.640 0.138
NFYB nuclear transcription factor Y, beta 292 0.626 0.143
PTPRK protein tyrosine phosphatase, receptor type, K 298 0.620 0.148
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 305 0.618 0.152
SYNJ1 synaptojanin 1 308 0.616 0.157
ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 312 0.609 0.162
SRPK2 SFRS protein kinase 2 333 0.592 0.165
EN2 engrailed homolog 2 353 0.579 0.168
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (p55, gamma) 363 0.571 0.172
ZNF652 zinc finger protein 652 390 0.553 0.175
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ATXN1 ataxin 1 399 0.548 0.179
AGGF1 angiogenic factor with G patch and FHA domains 1 421 0.535 0.182
LYST lysosomal trafficking regulator 422 0.535 0.186
ARF1 ADP-ribosylation factor 1 469 0.512 0.187
CALM3 calmodulin 3 (phosphorylase kinase, delta) 520 0.484 0.187
MTF2 metal response element binding transcription factor 2 531 0.482 0.190
GALNT7U P-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7 (GalNAc- 544 0.477 0.193
INSIG1 insulin induced gene 1 563 0.465 0.195
WDR37 WD repeat domain 37 578 0.458 0.198
MFHAS1 malignant fibrous histiocytoma amplified sequence 1 580 0.458 0.202
ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 593 0.453 0.204
MKL2 MKL/myocardin-like 2 595 0.452 0.208
MMD monocyte to macrophage differentiation-associated 598 0.451 0.212
FBXO28 F-box protein 28 637 0.436 0.212
TBL1XR1 transducin (beta)-like 1X-linked receptor 1 655 0.431 0.214
NUCKS1 nuclear casein kinase and cyclin-dependent kinase substrate 1 661 0.429 0.218
EXOC5 exocyst complex component 5 681 0.424 0.220
TIA1 TIA1 cytotoxic granule-associated RNA binding protein 687 0.422 0.223
ARMC1 armadillo repeat containing 1 721 0.410 0.223
JARID2 jumonji, AT rich interactive domain 2 726 0.408 0.227
RBL2 retinoblastoma-like 2 (p130) 737 0.405 0.229
DYNLT3 dynein, light chain, Tctex-type 3 740 0.404 0.232
OTUD4 OTU domain containing 4 741 0.404 0.236
H3F3B H3 histone, family 3B (H3.3B) 751 0.400 0.238
G3BP2 - 757 0.398 0.241
PCGF3 polycomb group ring finger 3 779 0.392 0.243
MITF microphthalmia-associated transcription factor 791 0.388 0.245
PDE4D phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 dunce homolog, Drosophila) 831 0.378 0.245
ZNF238 zinc finger protein 238 857 0.371 0.246
REV3L REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 871 0.368 0.248
PHF17 PHD finger protein 17 911 0.359 0.248
CHMP7 CHMP family, member 7 921 0.356 0.250
PAIP1 poly(A) binding protein interacting protein 1 945 0.351 0.251
CASK calcium/calmodulin-dependent serine protein kinase (MAGUK family) 966 0.345 0.253
QKI quaking homolog, KH domain RNA binding (mouse) 976 0.343 0.255
CASD1 CAS1 domain containing 1 978 0.342 0.257
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CPEB1 cytoplasmic polyadenylation element binding protein 1 997 0.337 0.259
EDNRB endothelin receptor type B 999 0.336 0.262
ATXN10 ataxin 10 1000 0.336 0.264
PANK3 pantothenate kinase 3 1010 0.334 0.266
MORC3 MORC family CW-type zinc finger 3 1023 0.331 0.268
VPS4B vacuolar protein sorting 4 homolog B (S. cerevisiae) 1028 0.330 0.271
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble 1056 0.325 0.271
CNOT2 CCR4-NOT transcription complex, subunit 2 1068 0.323 0.273
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 1098 0.317 0.273
CEP350 centrosomal protein 350kDa 1099 0.317 0.276
PHF15 PHD finger protein 15 1107 0.316 0.278
DAG1 dystroglycan 1 (dystrophin-associated glycoprotein 1) 1149 0.309 0.277
ZNF532 zinc finger protein 532 1151 0.308 0.280
RSBN1 round spermatid basic protein 1 1172 0.303 0.281
ZFYVE21 zinc finger, FYVE domain containing 21 1173 0.303 0.283
EIF4G2 eukaryotic translation initiation factor 4 gamma, 2 1231 0.292 0.281
CDK6 cyclin-dependent kinase 6 1254 0.287 0.282
DDHD2 DDHD domain containing 2 1284 0.282 0.282
PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 1314 0.278 0.282
ROBO2 roundabout, axon guidance receptor, homolog 2 (Drosophila) 1341 0.274 0.282
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 1398 0.262 0.280
CCNJL cyclin J-like 1404 0.261 0.281
CNIH cornichon homolog (Drosophila) 1407 0.261 0.283
RANBP9 RAN binding protein 9 1422 0.259 0.284
WNT5A wingless-type MMTV integration site family, member 5A 1425 0.259 0.286
CCNC cyclin C 1428 0.258 0.288
TBC1D12 TBC1 domain family, member 12 1447 0.255 0.289
1 Rank in Gene List refers to position of gene in list of β4-regulated mRNAs ranked in order of greatest change in expression
2 Rank Metric Score is the score used to position the genes in the ranked list
3 Running Enrichment Score (ES) reflects the degree to which the gene is overrepresented in the top of the ranked list of genes
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CHAPTER III 
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Abstract 
The α6β4 integrin (referred to as ‘β4’ integrin) is a receptor for laminins that 
promotes carcinoma invasion through its ability to regulate key signaling pathways and 
cytoskeletal dynamics.  An analysis of published Affymetrix GeneChip data to detect 
downstream effectors involved in β4-mediated invasion of breast carcinoma cells 
identified SPARC, or secreted protein acidic and rich in cysteine.  This glycoprotein has 
been shown to play an important role in matrix remodeling and invasion. Our analysis 
revealed that manipulation of β4 integrin expression and signaling impacted SPARC 
expression, and that SPARC facilitates β4-mediated invasion.  Expression of β4 in β4-
deficient cells reduced the expression of a specific microRNA (miR-29a) that targets 
SPARC and impedes invasion.  In cells that express endogenous β4, miR-29a expression 
is low and β4 ligation facilitates the translation of SPARC through a TOR-dependent 
mechanism.  The results obtained in this study demonstrate that β4 can regulate SPARC 
expression and that SPARC is an effector of β4-mediated invasion.  They also highlight a 
potential role for specific miRNAs in executing the functions of integrins.  
 
Introduction   
Integrins are a family of heterodimeric transmembrane cell surface receptors 
composed of α and β subunits that collectively link the cytoskeleton to components in the 
extracellular matrix or to neighboring cells (131, 132).  The integrin α6β4, referred to as 
‘β4 integrin,’ is an adhesion receptor for the laminins that plays a pivotal role in both 
normal tissue development and homeostasis, as well as in carcinoma progression (85, 
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188).  β4 mediates the formation of HDs, inert structures on the basal surface of epithelial 
cells anchoring the intermediate cytoskeleton to laminins in the basement membrane 
(133, 134).  Factors in the tumor microenvironment of invasive carcinomas liberate β4 
from HDs and promote its relocalization to the leading edge of cells, where it becomes 
signaling competent and associates with F-actin in lamellae and filopodia to promote 
migration and invasion (58, 85, 86, 135-137).  In the context of breast cancer, this 
integrin is associated with a “basal-like” subset of tumors, and its expression predicts 
decreased time to tumor recurrence as well as decreased patient survival (138).  The 
contributions of β4 to carcinoma progression stem, in part, from its ability to regulate the 
expression and function of downstream effector molecules (53, 63, 78, 79, 85, 98, 102).  
We conducted an analysis of published Affymetrix GeneChip data (76) and 
identified SPARC, or secreted glycoprotein acidic and rich in cysteine as a potential 
effector of β4-mediated function.  SPARC plays a key role in extracellular matrix 
remodeling and cell motility (189).  The data we obtained demonstrate that β4 expression 
and ligation can regulate SPARC and that SPARC is an effector of β4-mediated invasion.  
Interestingly, SPARC was identified as a target of miR-29a in osteoblasts (190), 
prompting us to examine the role of miRNAs downstream of β4 in the regulation of 
SPARC.  miRNAs are non-coding single-stranded RNAs approximately 22 base pairs in 
length that regulate gene expression through mRNA degradation or translational 
inhibition and have been shown to play an increasingly significant role in tumorigenesis 
(108, 123).  We identify miR-29a as a β4-regulated miRNA that can influence SPARC 
expression and invasion.  The regulation of miR-29a by β4 is seen in cells that exhibit 
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high miR-29a expression; in cells that express endogenous β4, miR-29a expression is 
low.  Finally, we provide evidence that β4 expression and ligation facilitate the 
translation of SPARC.   
 
Results  
β4 integrin regulates expression of SPARC  
 MDA-MB-435 breast carcinoma cells were utilized initially as a model system to 
identify β4-regulated genes that facilitate invasion.  Despite some reports claiming that 
these cells are of melanocytic origin (191-193), several reports have refuted this claim 
and have provided convincing data that this is a poorly differentiated cell line of breast 
cancer origin (194-198).  These cells express α6β1 endogenously but lack α6β4.  
Introduction of the β4 subunit leads to preferential heterodimerization of the α6 subunit 
with the β4 subunit (33, 142).  Stable subclones were generated expressing wild-type β4  
(referred to as β4 transfectants) or a β4 deletion mutant  (referred to as β4ΔCYT 
transfectants) that lacks the cytoplasmic domain of the β4 subunit.  This deletion impedes 
the signaling capacity of the integrin, and it eliminates the formation of the α6β1 
heterodimer (53, 199).  Mock transfectants were also generated.  The β4 transfectants are 
significantly more invasive than either the mock or β4ΔCYT transfectants (53). 
To identify potential regulators of β4-mediated invasion, we conducted an 
analysis of published Affymetrix GeneChip data that were obtained using the MDA-MB-
435/β4 transfectants (76).  SPARC, or secreted protein acidic and rich in cysteine, was 
identified using this approach.  This secreted glycoprotein is involved in extracellular 
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matrix remodeling and invasion (189).  SPARC mRNA and protein expression was 
examined to determine whether β4 differentially regulates its expression in this system.  
Quantitative real time PCR (qPCR) confirmed that SPARC message levels are elevated 
over 3-fold in the β4 transfectants compared to controls (Fig. 3.1A).  Furthermore, 
SPARC protein expression is elevated significantly in the total cell extract and culture 
media of the β4 transfectants compared to either the mock or β4ΔCYT transfectants (Fig. 
3.1B), providing evidence that the β4 integrin can induce SPARC expression.  
β4 expression inversely correlates with miR-29a expression 
SPARC was recently identified as a target of miR-29a in osteoblasts (190), 
prompting us to examine the role of miRNAs downstream of β4 in the regulation of 
SPARC.  SPARC contains two conserved miR-29 predicted miRNA binding sites and 
one conserved miR-203 predicted binding site in its 3’UTR.  These observations are 
relevant because of results from a miRNA microarray conducted by our laboratory to 
assess global miRNA expression in the MDA-MB-435/β4 system.  Specifically, two 
subclones of the β4 transfectants (3A7 and 5B3) and two subclones of the mock 
transfectants (6D2 and 6D7), as well as the MDA-MB-435 parental cells, were examined 
using a novel microarray technology termed qNPA.  The results of the array 
demonstrated that β4 expression repressed the expression of miR-29a and miR-29b (Fig. 
3.2A).  miR-29c and miR-203 levels, however, were unchanged (data not shown).   We 
focused on miR-29a because it has been shown to target SPARC and because miR-29b 
undergoes rapid decay following nuclear import in cycling cells (200).   The microarray 
data were confirmed using qPCR.  The expression of β4 in MDA-MB-435 cells resulted 
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in an approximate 4-fold decrease in miR-29a compared to the mock transfectants.  
Furthermore, a subclone of the β4ΔCYT transfectants (5D5) was also examined and 
found to express levels of miR-29a similar to those detected in the mock transfectants 
(Fig. 3.2B), indicating that the cytoplasmic tail of β4 is required for repression of miR-
29a.  
To assess the relationship between β4 and miR-29a expression further, we 
examined a series of breast carcinoma cell lines with differential β4 expression.  The β4-
null MDA-MB-435 parental cells were compared to the β4-null SUM1315 breast 
carcinoma cell line, and to the β4-expressing MDA-MB-231 and SUM-159 breast 
carcinoma cell lines (Fig. 3.2C).  Levels of miR-29a were markedly lower in cell lines 
expressing β4 compared to those not expressing the integrin (Fig. 3.2D), supporting a 
relationship between β4 expression and the regulation of miR-29a.  
Gene set enrichment analysis of the published Affymetrix GeneChip data (76) 
was conducted to substantiate the role of miR-29a in the regulation of β4-mediated 
targets.  This analysis examines the population of β4-regulated mRNAs for an over-
representation of genes predicted to be targeted by our miRNA of interest.  Our analysis 
revealed a significant enrichment (p < 0.001) for miR-29 predicted targets in mRNAs 
upregulated by β4 (Fig. 3.3).  In contrast, no enrichment was detected for miR-93, a 
miRNA selected as a negative control on the basis that it was expressed at robust levels in 
all samples (data not shown).  As part of this analysis, a list of leading edge genes was 
generated, consisting of a group of mRNAs that are the important contributors to the 
detected enrichment.  The list of leading edge genes contained 116 mRNAs (Table S3.1), 
71
the top 25 of which are listed in Table 3.1 ranked in order of contribution to the detected 
enrichment.  As anticipated, SPARC appears on this list.  Of interest, other genes in this 
table have also been implicated in the invasive process in breast carcinoma and other 
cancers, including LOXL2 and MAPRE2 (201-206).  COL1A2 appears on this list as 
well and has been linked to increased cell motility and metastatic disease (207, 208).  
These observations raise the possibility that miR-29a regulates a pro-invasive pool of 
target genes, and that SPARC actively cooperates with many of these molecules to 
promote carcinoma invasion.   
β4-mediated repression of miR-29a can promote SPARC-dependent invasion 
The findings described above raised the issue of whether miR-29a represses 
invasion by targeting SPARC.  To test the hypothesis that repression of miR-29a is 
required for invasion, a synthetic chemically-modified miRNA mimic was used to 
overexpress the mature form of miR-29a in the MDA-MB-435/β4 transfectants.  
Transfection of the β4 transfectants with the miR-29a mimic decreased invasion 6.6-fold 
compared to cells transfected with a non-specific negative control mimic (Fig. 3.4A).  
These findings were extended to SUM-159 cells, an invasive breast carcinoma cell line 
that endogenously expresses β4 and contains levels of miR-29a similar to those of the β4 
transfectants (Figs. 3.2B, 3.2C, and 3.4A).  We then pursued the possibility that loss of 
functional miR-29a is sufficient to induce an invasive phenotype.  Mock transfectants, 
which are poorly invasive and express relatively high levels of miR-29a, were transfected 
with a miR-29a functional inhibitor.  This hairpin inhibitor is an RNA oligonucleotide 
designed to inhibit the function of the endogenous miRNA.  Expression of the inhibitor 
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diminishes levels of functional miR-29a and, thus, mimics β4-induced miR-29a 
repression.  The results from this experiment demonstrate that inhibition of miR-29a is 
not sufficient to induce the invasive phenotype of cells in the absence of β4 (Fig. 3.4B), 
consistent with our observation that overexpression of SPARC in the mock transfectants 
resulted in no change in invasion (data not shown).  
To establish that miR-29a represses SPARC as a function of β4 expression, 
SPARC expression was examined following manipulation of miR-29a levels in both the 
MDA-MB-435/β4 and mock transfectants.  Transfection of the β4 transfectants with the 
miR-29a mimic produced a significant decrease in SPARC expression compared to mock 
transfected cells and cells transfected with a non-specific negative control mimic (Fig. 
3.4C).  Conversely transfection of the mock transfectants with a miR-29a inhibitor 
substantially increased SPARC expression compared to mock transfected cells and cells 
transfected with a non-targeting negative control inhibitor (Fig. 3.4C).  Importantly, these 
data substantiate the invasion assays described above by confirming that the mimic and 
hairpin inhibitor are functional, since functionality is established by their ability to 
regulate target gene expression.  Furthermore, the protein data from the inhibitor studies 
provide a control for the invasion assay presented in Figure 3.4B, insuring that the poorly 
invasive phenotype of the cells transfected with the miR-29a inhibitor is not due to a 
technical problem with the inhibitor. 
To determine whether SPARC is necessary for β4-mediated invasion, β4 
transfectants were subjected to an invasion assay following incubation with a functional 
blocking antibody to SPARC.  The ability of these cells to invade Matrigel was decreased 
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2.5-fold compared to cells receiving no treatment and cells pre-incubated with normal 
mouse IgG (Fig. 3.4D), establishing a role for this β4 target in mediating invasion 
downstream of the integrin.   
β4 can regulate SPARC independently of miR-29a  
Although the β4 transfectants possess some constitutive activity and can mediate 
β4-function in a ligand independent manner (78, 88), ligation of β4 either by adhesion to 
laminin or antibody-mediated clustering should in principle further repress miR-29a and 
upregulate SPARC expression.  Interestingly, our data indicate that β4 signaling can 
upregulate SPARC expression independently of the miRNA.  As depicted in Figure 3.5A, 
ligation of β4 in the β4 transfectants by adhesion to laminin induces SPARC protein 
expression compared to suspension control.  Given that the β4 transfectants retain 
expression of the β1 integrin subunit (53), antibody-mediated clustering experiments 
were conducted to substantiate these data and further implicate β4 signaling in the 
regulation of this effector molecule.  Specifically, clustering with an antibody to the α6 
subunit of the integrin (mAb 2B7) upregulates SPARC protein compared to cells 
clustered with an antibody to β1 (mAb AIIB2), confirming that this regulation is specific 
to integrin α6β4 (Fig. 3.5A). 
Our observation that SPARC induction occurs in the absence of further miR-29a 
repression (data not shown) prompted us to examine the expression of SPARC message 
under these conditions.  SPARC mRNA levels are unchanged in cells clustered with the 
α6 antibody compared to the β1 control (Fig. 3.5B), suggesting that β4 plays a role in 
regulating SPARC protein stability or translation.  Considering that ligation of this 
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integrin is known to upregulate mTOR signaling and VEGF translation (95), we treated 
cells with rapamycin, an inhibitor of TOR cap-dependent translation.  As depicted in 
Figures 3.5A and 3.5B, rapamycin blocked β4-mediated induction of SPARC protein, as 
well as pS6K and p4E-BP1 signaling intermediates.  Our data suggest that while steady-
state levels of SPARC can be regulated by miR-29a in this system, rapid changes in 
SPARC expression occurring in response to β4 ligation arise through a TOR-dependent 
translational mechanism. 
We next assessed the relationship between β4 and SPARC in breast carcinoma 
cells that express endogenous β4.  For this purpose, the SUM-159 cell line was selected 
because it is an invasive breast carcinoma cell line in which SPARC is robustly expressed 
(Fig. 3.5D). Interestingly, transient depletion of β4 using siRNA diminished SPARC 
protein expression but it had no effect on SPARC mRNA levels (Figs. 3.5C and 3.5D).  
These data support the hypothesis that β4 can regulate SPARC expression.  Depletion of 
β4 expression, however, did not increase miR-29a (data not shown).  Based on our 
observation that β4 can regulate SPARC independently of the miRNA in the MDA-MB-
435 system, we examined the possibility that this translational mechanism was also at 
play in the SUM-159 cells.  As depicted in Fig. 3.5D, levels of pS6K and p4E-BP1 
signaling intermediates were diminished upon loss of β4.  To establish that this pathway 
is required for maintenance of SPARC expression, SUM-159 parental cells were treated 
with rapamycin.  After six hours, a detectable decrease in SPARC protein levels was 
observed (Fig. 3.5E), suggesting that β4 regulates SPARC expression in this system 
through a TOR-dependent translational mechanism. 
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To assess the role of β4 ligation and signaling in regulating SPARC translation in 
SUM-159 cells, these cells were plated on laminin in the presence or absence of 
rapamycin.  Work from our laboratory has established that α6β4 is the predominant 
laminin-binding integrin in these cells (96).  Laminin-mediated clustering of β4 induces 
SPARC expression at the protein level compared to suspension control (Fig. 3.5F), while 
SPARC mRNA levels remain unaffected (Fig. 3.5G).  As anticipated, this induction is 
abrogated upon treatment with rapamycin (Fig. 3.5F). 
 
Discussion   
The major conclusion of this study is that the β4 integrin can regulate the 
expression of SPARC in breast carcinoma cells.  This finding is significant because this 
integrin is known to facilitate the invasion of carcinoma cells, and its regulation of 
SPARC adds to our understanding of how β4 can contribute to the invasive process.  In 
addition, our data reveal a novel function for the β4 integrin in repressing the expression 
of a specific miRNA, miR-29a that can impede invasion.  To our knowledge, this is the 
first report that integrins can regulate the expression of miRNAs.  One mechanism by 
which miR-29a impedes invasion is to target SPARC.  This mode of miR-29a regulation 
by β4 is manifested in cells that express high levels of miR-29a.  In other cells that 
express endogenous β4 and low levels of miR-29a, we provide evidence that β4 
expression and signaling can enhance SPARC translation.  These findings indicate that 
β4 has the ability to regulate SPARC expression by distinct mechanisms. 
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Our data support the notion that SPARC, a secreted extracellular matrix 
glycoprotein with counter-adhesive properties, functions to promote invasion.  This role 
for SPARC is supported by the findings that SPARC can promote cell motility and 
invasion in various carcinoma cells, including breast (209-216).  Moreover, SPARC 
expression has been associated with basal-like breast cancers (217).  This observation is 
relevant to our findings because we correlated β4 integrin expression with basal-like 
breast cancers in a previous study (138), and the cell lines used in the current study 
exhibit a basal phenotype.  Some reports, however, have questioned the role of SPARC in 
breast cancer invasion and progression (218, 219).  SPARC has also been shown to 
decrease the mitogenic potency of various growth factors including VEGF and platelet-
derived growth factor (PDGF) by antagonizing their ability to bind to their cognate 
receptors (220, 221).  In contrast, there is evidence that SPARC can enhance integrin and 
growth factor receptor-regulated kinases, thereby upregulating key signaling pathways 
involved in cell motility (215, 222-226), observations that are consistent with our data.  
This dichotomy of SPARC function may be explained by the hypothesis that SPARC 
inhibits early stages of tumorigenesis but potentiates later stages of progression, 
analogous to the TGF-β pathway (227), a growth factor signaling pathway that SPARC 
has been shown to regulate (226, 228-232).  
Our data provide the first indication that β4 has the ability to regulate the 
expression of specific miRNAs and that such miRNAs can influence β4-mediated 
migration and invasion.   Since the initial reports that the β4 integrin has the ability to 
promote the migration and invasion of epithelial and carcinoma cells, numerous 
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mechanisms have been reported to account for this phenomenon.  These mechanisms 
include activation of signaling pathways, especially the PI3K pathway and Rho GTPases, 
transcription factors (NFAT), and cap-dependent translation of key effector molecules 
(53, 74, 78, 79, 95, 233, 234).  The ability of β4 to regulate the expression of miRNAs 
adds a new dimension to our understanding of how β4 mediates invasion and other 
functions.  The repression of miR-29a that occurs in response to exogenous expression of 
β4 is significant in this context because miR-29a represses invasion and targets SPARC.  
While our data indicate that β4-mediated repression of miR-29a is required for invasion, 
our observation that functional inhibition of this miRNA did not induce an invasive 
phenotype in the poorly invasive, mock transfectants suggests that a single miRNA is 
unlikely to be solely responsible for a cellular process.  Although we observed that this 
regulation of miR-29a by β4 is manifested in specific cell types, especially those that 
express high levels of miR-29a, the paradigm that miRNAs contribute to the execution of 
integrin-mediated functions may be widespread. 
The half-life of specific miRNAs could be a significant factor in their potential 
repression by integrin signaling.  Given that the reported half-life of miR-29a is greater 
than 12 hours (200), a detectable decrease in miR-29a following the transient signaling 
events induced by integrin ligation would require degradation of the pre-existing miRNA.  
This assumption is supported by our result that antibody-mediated clustering of β4 on 
MDA-MB-435 cells for times up to four hours had no significant effect on miR-29a 
expression.  We surmise from these data that exogenous expression of β4 in β4-deficient 
cells results in a long-term and sustained repression of miR-29a expression.  This 
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possibility is supported tangentially by our finding that the expression pattern of β4 in 
breast carcinoma cell lines correlates inversely with miR-29a expression, and previous 
reports that β4-mediated signaling and function can occur independently of its ligation 
(78, 88).  It is also worth noting in this regard our analysis of published microarray data 
that revealed a significant enrichment in miR-29a predicted targets in mRNAs 
upregulated by expression of β4. This finding suggests that a miRNA can broadly affect 
gene expression downstream of an integrin and corroborate the importance of miR-29a in 
the regulation of genes whose expression is mediated by β4. 
We also provide evidence that SPARC can be regulated at the level of protein 
translation by β4, particularly in cells that express endogenous β4 and low levels of miR-
29a.  Ligation of β4 by adhesion to laminin or antibody-mediated clustering upregulates 
SPARC protein expression in both MDA-MB-435/β4 transfectants as well as SUM-159 
cells.  This finding is consistent with a previous report demonstrating that β4 can 
facilitate the cap-dependent translation of VEGF in breast carcinoma cells (95).  In 
principle, this mode of regulation would enable SPARC expression to be altered rapidly 
in response to microenvironmental cues that impact β4. Moreover, the β4-mediated 
regulation of SPARC by miRNA repression and cap-dependent translation mechanisms 
need not be mutually exclusive.   
 
Materials and Methods   
Cell Lines, Antibodies, and Reagents: MDA-MB-435 and MDA-MB-231 cells were 
obtained from the Lombardi Cancer Center (Georgetown University, Washington, DC).  
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SUM-159 and SUM1315 cells were obtained from Dr. Stephen Ethier (Wayne State 
University School of Medicine, Detroit, MI).  MDA-MB-435 and MDA-MB-231 cell 
lines were maintained in low glucose DMEM medium (Gibco, Carlsbad, CA) 
supplemented with 10 mM HEPES, 5% fetal bovine serum, and 1% streptomycin and 
penicillin.  SUM-159 were maintained in Ham’s F12 medium (Gibco) supplemented with 
5% fetal bovine serum, insulin (5 µg/ml), hydrocortisone (1 µg/ml), and 1% streptomycin 
and penicillin.  SUM1315 cells were maintained in Ham’s F12 medium (Gibco) 
supplemented with 5% fetal bovine serum, insulin (5 µg/ml), EGF (10 ng/ml), and 1% 
streptomycin and penicillin.  All cell lines were grown at 37°C in an incubator supplied 
with 5% CO2.  MDA-MB-435 mock transfectants (6D2 and 6D7 sublcones), β4 
transfectants (3A7 and 5B3 subclones), and β4ΔCYT transfectants (5D5) were generated 
and characterized as previously described (53). Antibodies to SPARC (Haematological 
Technologies, Essex Junction, VT), pS6K (Cell Signaling, Beverly, MA), p4E-BP (Cell 
Signaling), tubulin (Sigma, St. Louis, MO), and actin (Sigma) were used for 
immunoblotting.  The same SPARC antibody was used as a functional blocking antibody 
for invasion assays.  The 505 antibody to β4, used for immunoblotting, and the 2B7 
antibody to α6, used for clustering, were produced by our laboratory as previously 
described (86, 182). The AIIB2 antibody to β1 (Development Studies Hybridoma Bank, 
University of Iowa, Iowa City, IA) was used for clustering experiments.  For inhibitor 
experiments, rapamycin (Sigma) was used at a concentration of 50 nM.   
Immunoblotting: Cells were solubilized on ice for 10 min in Triton X-100 lysis buffer 
(Boston Bioproducts, Ashland, MA) containing 50 mM Tris buffer, pH 7.4, 150 mM 
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NaCl, 5mM EDTA, 1% Triton X-100, and protease inhibitors (Complete mini tab; Roche 
Applied Science, Indianapolis, IN) (Lysis Buffer A).  Nuclei were removed by 
centrifugation at 16,100 × g for 10 min.  Culture media was concentrated 8-fold using 
Ultra-4 Centrifugal Filter Units with a 10 kDa cutoff by spinning at 340 × g for 25 min 
(Millipore, Indianapolis, IN).  Concentrations of total cell lysate and culture media were 
assayed by Bradford method.  Lysates (50 µg) and concentrated culture media (25 ug) 
were separated by electrophoresis through 10% SDS-PAGE and transferred to 0.2 µm 
nitrocellulose membranes (Bio-Rad, Hercules, CA).  Membranes were blocked in 5% 
nonfat milk in Tris-buffered saline/Tween 20 for 1 h and blotted with the antibodies to 
SPARC (1:10,000), pS6K (1:500), p4E-BP (1:1000), β4 (1:4,000), actin (1:5,000), or 
tubulin (1:10,000) overnight at 4°C.  Proteins were detected by enhanced 
chemiluminescence (Pierce, Rockford, IL) after incubation for 1 h with horseradish 
peroxidase-conjugated secondary antibodies. 
miRNA and RNA Isolation and Detection: Total RNA was isolated using the miRVana 
RNA Isolation Kit according to manufacturer protocol (Ambion).  qPCR detection of 
mature miRNAs was performed using TaqMan miRNA Reverse Transcription Kit and 
TaqMan human Microarray Assays for miR-29a (Applied Biosystems, Austin, TX) 
according to manufacturer protocol.  U6 small nuclear RNA was used as an internal 
control.  qPCR detection of SPARC mRNA was performed using Superscript II reverse 
transcriptase (Invitrogen) and Power SYBR Green (Applied Biosystems) according to 
manufacturer protocol.  GAPDH was used as an internal control.  miRNA and SPARC 
expression levels were quantified using the ABI Prism 7900HT Sequence detection 
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system (Applied Biosystems).  Primers to SPARC (5’-AGCACCCCATTGACGGGTA-
3’ and 5’-GGTCACAGGTCTCGAAAAAGC-3’) and GAPDH (5’-
ATCATCCCTGCCTCTACTGG-3’ and 5’-GTCAGGTCCACCACTGACAC-3’) were 
used for analysis.  
Gene Set Enrichment Analysis: For miRNA target enrichment analysis, mRNA 
expression data generated by Chen et. al. (76) were downloaded from the NCBI Gene 
Expression Omnibus (GEO), series number GSE11466.  Affymetrix CEL files were 
processed with the robust multi-chip average (RMA) algorithm (186) using BRB-
ArrayTools.  TargetScanHuman Release 5.1 (235, 236) was used to predict conserved 
mRNA targets.  Using total context score, the top 500 targets for miR-29 or miR-93 were 
compiled into gene set lists.  miR-93 targets were used as a negative control gene set 
because miR-93 is highly abundant, yet it did not change expression in the β4 versus 
mock miRNA array analysis.  Log base 2 mRNA data was loaded into the Broad 
Institute’s Gene Set Enrichment Analysis (GSEA) software v2.06 (163, 187).  β4 
phenotype was compared to mock phenotype by first collapsing the dataset to gene 
symbols and then using a weighted, difference of classes metric for ranking genes.  Gene 
set permutations were performed to generate nominal p-values for each miRNA target 
gene set list.  
Oligonucleotide Transfection: miRIDIAN- microRNA Mimics are synthetic chemically 
modified mature miRNAs (Dharmacon, Lafayette, CO).  MDA-MB-435 β4 transfectants 
were transfected with 20 nM hsa-miR-29a mimic or a miRNA mimic negative control at 
50% confluency using DharmaFECT 4 Transfection Reagent (Dharmacon).  At 72 h 
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post-transfection, cells were plated for invasion assays or harvested for total cell lysate.  
A miRIDIAN microRNA Hairpin Inhibitor to mature miR-29a was used for loss-of-
function analyses along with a hairpin inhibitor negative control (Dharmacon).  MDA-
MB-435 mock transfectants were transfected with 20 nM miR-29a inhibitor or negative 
control inhibitor as described above. At 72 h post-transfection, cells were harvested for 
protein or total RNA as described above. 
Invasion Assays: The upper surfaces of the transwells were coated with 0.5 µg Matrigel 
(BD Biosciences, Bedford, MA) and allowed to dry overnight at room temperature.  Cells 
were harvested at 80% confluency by trypsinization and resuspended low glucose 
DMEM containing 0.25% heat-inactivated fatty acid-free bovine serum albumin.  The 
coated surfaces of the transwells were blocked with media containing bovine serum 
albumin for 60 min at 37°C.  For SPARC blocking antibody experiments, cells were 
incubated with 16 ug/ml of SPARC antibody (Haematological Technologies) or normal 
mouse IgG for 30 min at room temperature with intermittent agitation.  105 cells in a total 
volume of 100 µl were loaded into the upper chamber and NIH-3T3 conditioned media 
was added to the lower chamber.  Assays proceeded for 4 h at 37°C.  At the completion 
of the assays, the upper chamber was swabbed to remove residual cells and fixed with 
methanol.  Cells on the lower surface of the membrane were mounted in 4′,6-diamidino-
2-phenylindole mounting media (Vector Laboratories, Burlingame, CA), and the number 
of cells was determined for five independent fields in triplicate with a 10X objective and 
fluorescence.  
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siRNA Experiments: SUM-159 cells were transfected with 20 nM On-TARGETplus 
SMARTpool siRNA targeting β4 (Dharmacon) at 50% confluency using DharmaFECT 4 
transfection reagent (Dharmacon).  A non-targeting siRNA pool (Dharmacon) was used 
as a control for these experiments.  At 72 h post-transfection, cells were harvested for 
protein or total RNA as described above. 
Integrin Clustering: MDA-MB-435/β4 and SUM-159 cells were serum starved overnight 
in DMEM containing 0.1% BSA and F12 containing 0.1% BSA, respectively.  Cells were 
trypsinized, washed, and the resuspended at a concentration of 106 cells/ml.  For laminin 
experiments, cells were plated on laminin (100 µg/10 cm plate) or maintained in 
suspension.  For antibody-mediated clustering experiments, cell suspensions were 
incubated for 30 minutes with integrin-specific antibodies (2 µg/ml) in DMEM 
containing 0.1% BSA.  The cells were washed and added to plates that had been coated 
overnight with anti-mouse or anti-rat IgG (33 µg/6 cm plate).  For both laminin and 
antibody-mediated clustering experiments, cells were treated with 50 nM Rapamycin or 
DMSO for 10 minutes prior to plating cells on coated plates. After incubation at 37°C for 
45 minutes, the cells were washed twice with PBS and lysed for protein in a 20 mM Tris 
buffer, pH 7.4, containing 10% glycerol, 136 mM NaCl, 10% NP-40, 1 mM sodium 
orthovanadate (Na3VO4), 10 mM sodium fluoride (NaF), 2 mM phenylmethanesulfonyl 
fluoride (PMSF), and complete protease inhibitor cocktail (Roche) (Lysis Buffer B) or 
for total RNA as described above. 
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Rapamycin Experiments: SUM-159 parental cells were treated with 50 nM Rapamycin or 
DMSO in serum-containing medium for four or six hours.  Cells were lysed using Lysis 
Buffer B and samples were prepared for analysis as described above.  
Statistical Analysis: Data are presented as the mean ± S.E. The Student's t test was used 
to assess the significance of independent experiments. The criterion p < 0.05 was used to 
determine statistical significance.  
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Table 3.1.  Top 25 leading edge genes 
Gene 
Symbol Gene Title
Rank in 
Gene 
List1
Rank 
Metric 
Score2
Running 
ES3
GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 17 1.607 0.020
SHROOM2 shroom family member 2 70 1.054 0.030
HDAC4 histone deacetylase 4 90 0.960 0.041
TRIM9 tripartite motif-containing 9 92 0.952 0.053
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 104 0.910 0.065
LOXL2 lysyl oxidase-like 2 113 0.873 0.075
FAM3C family with sequence similarity 3, member C 121 0.859 0.086
DCP2 DCP2 decapping enzyme homolog (S. cerevisiae) 134 0.829 0.096
TUBB2A tubulin, beta 2A 149 0.798 0.106
HMGN3 high mobility group nucleosomal binding domain 3 152 0.796 0.116
COL1A2 collagen, type I, alpha 2 153 0.795 0.126
KCTD3 potassium channel tetramerisation domain containing 3 158 0.786 0.137
MAPRE2 microtubule-associated protein, RP/EB family, member 2 169 0.769 0.146
GMFB glia maturation factor, beta 193 0.733 0.154
COL5A2 collagen, type V, alpha 2 196 0.727 0.163
FRAT2 frequently rearranged in advanced T-cell lymphomas 2 226 0.690 0.170
MLF1 myeloid leukemia factor 1 266 0.657 0.176
CNOT8 CCR4-NOT transcription complex, subunit 8 270 0.654 0.184
ZFP36L1 zinc finger protein 36, C3H type-like 1 279 0.644 0.192
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 280 0.640 0.200
LAMC1 laminin, gamma 1 (formerly LAMB2) 283 0.638 0.209
PURA purine-rich element binding protein A 295 0.623 0.216
RERE arginine-glutamic acid dipeptide (RE) repeats 306 0.617 0.223
GAS7 growth arrest-specific 7 315 0.607 0.231
PPIC peptidylprolyl isomerase C (cyclophilin C) 316 0.606 0.239
1 Rank in Gene List refers to position of gene in list of mRNAs ranked in order of greatest 
change in expression
2 Rank Metric Score is the score used to position the genes in the ranked list
3 Running Enrichment Score (ES) reflects the degree to which the gene is overrepresented
 in the top of the ranked list of genes
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Figure 3.1.  β4 integrin regulates expression of SPARC.  A, Relative expression of 
SPARC mRNA by qPCR in mock, β4ΔCYT, and β4 transfectants, *, p < 0.04.  B, 
Expression of SPARC in total cell extract (50 µg) and culture medium (25 µg) across 
MDA-MB-435 subclones.   
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Figure 3.2.  β4 expression inversely correlates with miR-29a expression.  A, miR-29a 
and miR-29b expression from qNPA microarray performed in triplicate on the MDA-
MB-435 parental cell line, two subclones of the MDA-MB-435 mock transfectants (6D2 
and 6D7), and two subclones of the MDA-MB-435 β4 transfectants (3A7 and 5B3).  B, 
Relative expression of miR-29a in two subclones of the mock transfectants, one subclone 
of the β4ΔCYT transfectants, and two subclones of the β4 transfectants based on qPCR, 
*, p < 0.001 when compared to average expression in mock transfectants.  C, Expression 
of β4 in total cell extract (50 µg) in MDA-MB-435, SUM1315, SUM-159, and MDA-
MB-231 breast carcinoma cell lines *, p < 0.004.  D, Relative expression of miR-29a in 
MDA-MB-435, SUM1315, SUM-159, and MDA-MB-231 breast carcinoma cell lines.  
Data represent means ± S.E. from three independent experiments. 
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 Figure 3.3.  Enrichment of miR-29 predicted targets in β4-regulated mRNAs.  
GeneChip derived mRNA levels were ranked from the most upregulated in β4 
transfectants to the most downregulated (x-axis, 1 to 12,300, respectively).  Red shading 
indicates mRNA is upregulated in β4 transfectants, while blue shading indicates mRNA 
is downregulated.  Each vertical black line represents a miRNA target predicted by 
TargetScan.  The left-to-right position of each black line indicates the relative position of 
the predicted target within the rank ordered mRNA list.  Left panel, the miR-29 predicted 
target gene set is enriched among mRNAs upregulated in the β4 transfectants, as 
illustrated by the increasing number of black lines on the left side and the positive 
running enrichment score (ES) marked by the green line (p < 0.001).  The leading edge 
subset, the 116 miR-29 targets that contribute the most to the ES, are found to the left of 
the gray dotted line.  Right panel, miR-93 predicted targets, used as a negative control 
gene set, did not show a significant enrichment (p = 0.438).
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Figure 3.4.  β 4-mediated repression of miR-29a can promote SPARC-dependent 
invasion.  A, β4 transfectants and SUM-159 cells were subjected to Matrigel invasion 
assays following transfection with a miR-29a mimic, *, p < 0.02.  B, Mock transfectants 
were subjected to Matrigel invasion assays following transfection with a miR-29a hairpin 
inhibitor.  Data for invasion assays represent means ± S.E. from a representative 
experiment.  C, Expression of SPARC in total cell lysate (50 µg) following expression of 
miR-29a mimic in β4 transfectants 72 hours post-transfection or expression of miR-29a 
hairpin inhibitor in mock transfectants 72 hours post-transfection.  D, β4 transfectants 
were subjected to Matrigel invasion assays following 30 minute pre-incubation with 
normal mouse IgG or a SPARC function blocking antibody, *, p < 0.001.  Data for 
invasion assay represents means ± S.E. from three independent experiments. 
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Figure 3.5.  β4 can regulate SPARC independently of miR-29a.  A, MDA-MB-435/β4 
cells were plated on laminin (LM) or maintained in suspension (S) for 45 minutes (left 
panel); MDA-MB-435/β4 cells were incubated with integrin-specific primary antibodies 
prior to plating on secondary antibody-coated plates for 45 minutes (right panel).  
Rapamycin (50 nM) or DMSO was added 10 minutes prior to plating.  Expression of 
SPARC and signaling intermediates in total cell extract (50 µg) was examined.  B, 
Relative expression of SPARC message levels by qPCR in MDA-MB-435/β4 cells 
clustered with integrin-specific antibodies.  C, Relative expression of SPARC message 
levels by qPCR following transient knockdown of β4 at 72 hours post-transfection in 
SUM-159 cells.  D, Expression of SPARC and signaling intermediates in total cell extract 
(50 µg) following transient knockdown of β4 at 72 hours post-transfection in SUM-159 
cells.  E, Expression of SPARC and signaling intermediates in total cell extract (50 µg) 
following treatment with 50 nM rapamycin.  F, SUM-159 cells were plated on laminin 
(LM) or maintained in suspension (S) for 45 minutes.  Rapamycin (50 nM) or DMSO 
was added 10 minutes prior to plating.  Expression of SPARC and signaling 
intermediates in total cell extract (50 µg) was examined.  G, Relative expression of 
SPARC message levels by qPCR in SUM-159 cells clustered on laminin (LM) or 
maintained in suspension. 
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Table S3.1.  miR-29a leading edge genes
Gene 
Symbol Gene Title
Rank in 
Gene List1
Rank Metric 
Score2
Running 
ES3
GPR37 G protein-coupled receptor 37 (endothelin receptor type B-like) 17 1.607 0.020
SHROOM2 shroom family member 2 70 1.054 0.030
HDAC4 histone deacetylase 4 90 0.960 0.041
TRIM9 tripartite motif-containing 9 92 0.952 0.053
MYBL2 v-myb myeloblastosis viral oncogene homolog (avian)-like 2 104 0.910 0.065
LOXL2 lysyl oxidase-like 2 113 0.873 0.075
FAM3C family with sequence similarity 3, member C 121 0.859 0.086
DCP2 DCP2 decapping enzyme homolog (S. cerevisiae) 134 0.829 0.096
TUBB2A tubulin, beta 2A 149 0.798 0.106
HMGN3 high mobility group nucleosomal binding domain 3 152 0.796 0.116
COL1A2 collagen, type I, alpha 2 153 0.795 0.126
KCTD3 potassium channel tetramerisation domain containing 3 158 0.786 0.137
MAPRE2 microtubule-associated protein, RP/EB family, member 2 169 0.769 0.146
GMFB glia maturation factor, beta 193 0.733 0.154
COL5A2 collagen, type V, alpha 2 196 0.727 0.163
FRAT2 frequently rearranged in advanced T-cell lymphomas 2 226 0.690 0.170
MLF1 myeloid leukemia factor 1 266 0.657 0.176
CNOT8 CCR4-NOT transcription complex, subunit 8 270 0.654 0.184
ZFP36L1 zinc finger protein 36, C3H type-like 1 279 0.644 0.192
SPARC secreted protein, acidic, cysteine-rich (osteonectin) 280 0.640 0.200
LAMC1 laminin, gamma 1 (formerly LAMB2) 283 0.638 0.209
PURA purine-rich element binding protein A 295 0.623 0.216
RERE arginine-glutamic acid dipeptide (RE) repeats 306 0.617 0.223
GAS7 growth arrest-specific 7 315 0.607 0.231
PPIC peptidylprolyl isomerase C (cyclophilin C) 316 0.606 0.239
SS18L1 synovial sarcoma translocation gene on chromosome 18-like 1 331 0.593 0.246
PER3 period homolog 3 (Drosophila) 337 0.587 0.253
PTP4A1 protein tyrosine phosphatase type IVA, member 1 339 0.587 0.261
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) 344 0.584 0.268
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TAF11 TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28kDa 351 0.582 0.275
CREB5 cAMP responsive element binding protein 5 373 0.563 0.281
ATXN1 ataxin 1 399 0.548 0.286
CYCS cytochrome c, somatic 406 0.543 0.293
DNMT3B DNA (cytosine-5-)-methyltransferase 3 beta 412 0.540 0.300
PDHX pyruvate dehydrogenase complex, component X 435 0.527 0.305
FEM1B fem-1 homolog b (C. elegans) 457 0.516 0.310
MAPRE1 microtubule-associated protein, RP/EB family, member 1 468 0.513 0.316
CALM3 calmodulin 3 (phosphorylase kinase, delta) 520 0.484 0.319
HISPPD1 Histidine acid phosphatase domain containing 1 545 0.474 0.323
BLMH bleomycin hydrolase 548 0.474 0.329
INSIG1 insulin induced gene 1 563 0.465 0.334
JARID1B jumonji, AT rich interactive domain 1B 592 0.453 0.338
RHOBTB1 Rho-related BTB domain containing 1 597 0.452 0.344
RNF138 ring finger protein 138 633 0.438 0.347
EIF4E2 eukaryotic translation initiation factor 4E member 2 646 0.434 0.351
TRIB2 tribbles homolog 2 (Drosophila) 660 0.429 0.356
PMP22 peripheral myelin protein 22 666 0.427 0.361
DAAM2 dishevelled associated activator of morphogenesis 2 702 0.417 0.364
JARID2 jumonji, AT rich interactive domain 2 726 0.408 0.368
AIM1 absent in melanoma 1 738 0.405 0.372
OTUD4 OTU domain containing 4 741 0.404 0.377
ZHX3 zinc fingers and homeoboxes 3 760 0.397 0.381
RARB retinoic acid receptor, beta 766 0.395 0.386
PCGF3 polycomb group ring finger 3 779 0.392 0.390
MLXIP MLX interacting protein 814 0.382 0.393
REV3L REV3-like, catalytic subunit of DNA polymerase zeta (yeast) 871 0.368 0.393
SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 873 0.368 0.398
IFI30 interferon, gamma-inducible protein 30 881 0.367 0.402
DDEF2 development and differentiation enhancing factor 2 889 0.364 0.407
BAT2D1 BAT2 domain containing 1 908 0.360 0.410
SLC36A1 solute carrier family 36 (proton/amino acid symporter), member 1 909 0.359 0.415
DICER1 Dicer1, Dcr-1 homolog (Drosophila) 937 0.353 0.417
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DYNLT1 dynein, light chain, Tctex-type 1 1089 0.319 0.410
LYPLA1 lysophospholipase I 1091 0.318 0.414
PGAP1 - 1123 0.314 0.416
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 1141 0.310 0.419
NUDT11 nudix (nucleoside diphosphate linked moiety X)-type motif 11 1146 0.309 0.422
BRWD1 bromodomain and WD repeat domain containing 1 1165 0.305 0.425
KIF26B kinesin family member 26B 1171 0.303 0.429
SNX4 sorting nexin 4 1204 0.298 0.430
TRIM37 tripartite motif-containing 37 1216 0.295 0.433
PLXNA1 plexin A1 1234 0.291 0.436
SNRK SNF related kinase 1248 0.288 0.438
CDK6 cyclin-dependent kinase 6 1254 0.287 0.442
KCTD5 potassium channel tetramerisation domain containing 5 1323 0.277 0.440
DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X-linked 1398 0.262 0.438
TDG thymine-DNA glycosylase 1406 0.261 0.441
KIAA0355 KIAA0355 1436 0.257 0.442
GSTA4 glutathione S-transferase A4 1462 0.253 0.443
PKNOX2 PBX/knotted 1 homeobox 2 1483 0.249 0.445
VANGL1 vang-like 1 (van gogh, Drosophila) 1503 0.246 0.447
ZNF282 zinc finger protein 282 1519 0.244 0.449
ISL1 ISL1 transcription factor, LIM/homeodomain, (islet-1) 1563 0.238 0.449
EPS15 epidermal growth factor receptor pathway substrate 15 1618 0.230 0.448
STX16 syntaxin 16 1625 0.229 0.450
CAV2 caveolin 2 1657 0.226 0.451
MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme A 1681 0.222 0.452
COL4A5 collagen, type IV, alpha 5 (Alport syndrome) 1695 0.221 0.454
ABHD4 abhydrolase domain containing 4 1759 0.213 0.452
CCNJ cyclin J 1776 0.211 0.453
SIP1 survival of motor neuron protein interacting protein 1 1812 0.207 0.453
ISG20L2 interferon stimulated exonuclease gene 20kDa-like 2 1846 0.205 0.454
LRP6 low density lipoprotein receptor-related protein 6 1850 0.204 0.456
RLF rearranged L-myc fusion 1870 0.202 0.457
NKTR natural killer-tumor recognition sequence 1871 0.202 0.460
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CPS1 carbamoyl-phosphate synthetase 1, mitochondrial 1899 0.200 0.460
NASP nuclear autoantigenic sperm protein (histone-binding) 2039 0.186 0.452
POLE3 polymerase (DNA directed), epsilon 3 (p17 subunit) 2047 0.184 0.454
KIAA0644 - 2050 0.184 0.456
NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 2084 0.180 0.456
CHFR checkpoint with forkhead and ring finger domains 2089 0.180 0.458
DBT dihydrolipoamide branched chain transacylase E2 2096 0.179 0.460
PARG poly (ADP-ribose) glycohydrolase 2106 0.178 0.462
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 2179 0.171 0.459
CCNT2 cyclin T2 2211 0.168 0.458
ELF2 E74-like factor 2 (ets domain transcription factor) 2213 0.168 0.461
BCORL1 BCL6 co-repressor-like 1 2243 0.166 0.460
COL2A1 collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, congenital) 2256 0.165 0.462
PLP1 proteolipid protein 1 (Pelizaeus-Merzbacher disease, spastic paraplegia 2, uncomplicated) 2289 0.162 0.461
PPP1R3D protein phosphatase 1, regulatory subunit 3D 2290 0.162 0.464
MEST mesoderm specific transcript homolog (mouse) 2322 0.158 0.463
JARID1A jumonji, AT rich interactive domain 1A 2346 0.156 0.464
ROBO1 roundabout, axon guidance receptor, homolog 1 (Drosophila) 2364 0.155 0.464
DNM3 dynamin 3 2378 0.154 0.465
UPK1B uroplakin 1B 2412 0.151 0.465
SOX12 SRY (sex determining region Y)-box 12 2415 0.151 0.467
1 Rank in Gene List refers to position of gene in list of β4-regulated mRNAs ranked in order of greatest change in expression
2 Rank Metric Score is the score used to position the genes in the ranked list
3 Running Enrichment Score (ES) reflects the degree to which the gene is overrepresented in the top of the ranked list of genes
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CHAPTER IV 
GENERAL DISCUSSION 
 
The integrin β4 was first identified as a tumor associated antigen whose 
expression correlated with metastatic disease (26).  This early observation was ostensibly 
at odds with its role as a mechanical device that maintained epithelial integrity.  Research 
over the past two decades has transformed our understanding of this integrin and 
characterized β4 as a dynamic cell surface receptor that mediates cytoskeletal 
organization and signal transduction, contributing to both physiological and pathological 
processes.  Its ability to potentiate carcinoma invasion is of particular importance and 
occurs in part through the regulation of downstream effector molecules.   
 
miRNA Expression Patterns 
The work presented in this dissertation documents the first example that integrin 
expression correlates with specific miRNA patterns.  Moreover, integrin β4 status in vitro 
and in vivo is associated with decreased expression of distinct miRNA families in breast 
cancer, namely miR-25/32/92abc/363/363-3p/367 and miR-99ab/100.  Further analysis 
identified overlapping predicted targets of these two miRNA families within a population 
of genes known to be downregulated by β4 based on published Affymetrix array data 
(76).  An overrepresentation of targets involved in cell migration was detected within this 
pool of genes, revealing unrecognized β4 targets potentially involved in promoting 
carcinoma progression.  Another miRNA, miR-29a, is significantly downregulated in 
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response to de novo expression of β4 in a breast carcinoma cell line.  Further study 
revealed that expression of this miRNA is inversely correlated with β4 status in several 
breast carcinoma cell lines.  β4-mediated repression of the miRNA is required for 
invasion, strengthening the link between miRNA expression patterns and cell motility 
downstream of β4 in the context of breast cancer.  Finally, gene set enrichment analysis 
detected an enrichment in predicted targets of several miRNA families identified by our 
screen, including miR-92ab and miR-29abc, within β4-regulated genes, substantiating the 
physiological significance of our data.  
An unexpected finding uncovered by our study is the observation that loss of β4 
in cells that endogenously express the integrin decreases the expression of miR-29a, 
results that are seemingly at odds with the aforementioned data.  Specifically, qNPA 
microarray analyses from SUM-159 breast carcinoma cells demonstrate a decrease in the 
expression of miR-29a upon transient depletion of β4, a finding confirmed by qPCR (data 
not shown).  Interestingly, family member miR-29b is also repressed.  Likewise, 
examination of the MCF10CA1a qNPA microarray identified a decrease in miR-29b and 
miR-29c in response to loss of β4 (Table 2-S1).   
Members of the miR-29 family of miRNAs are transcribed from two bicistronic 
loci, the miR-29b-1/a cluster on chromosome 7 and the miR-29b-2/c cluster on 
chromosome 1.  Therefore, miR-29a is generated exclusively from the miR-29b-1/a 
cluster, while miR-29c is generated exclusively from the miR-29b-2/c cluster.  Mature 
miR-29b, on the other hand, can be derived from transcription at either loci.  The array 
data, thus, illustrate a scenario involving β4-dependent maintenance of miR-29b 
100
expression through regulation at distinct transcriptional loci.  As miRNA family members 
share seed regions and therefore largely overlapping pools of putative targets, one 
hypothesis extending from our finding is that two highly aggressive breast carcinoma cell 
lines have evolved distinct mechanisms to repress a population of genes through 
sustained expression of miR-29 family members.   
Regarding transcriptional regulation of these family members, efforts early in the 
course of our study were invested in exploring the role of β4 in the regulation of the miR-
29b-1/a cluster by β4.  Our initial observation that expression of the integrin in MDA-
MB-435 cells repressed both miR-29a and miR-29b prompted us to consider potential 
downstream effectors of β4 that might be involved in transcriptional repression.  An 
obvious candidate was NFAT, a transcription factor with an established role in promoting 
β4-mediated invasion in this system (74).  More recently, it has been shown to regulate 
the transcription of β4 targets including autotaxin/ENPP2 and S100A4/metastasin (75-
77).   
The NFAT family of transcription factors is comprised of five known members.  
With the exception of NFAT5, all are responsive to fluctuations in intracellular Ca++ 
concentration.  NFAT is activated upon deposphorylation by the upstream calcium-
responsive phosphatase calcineurin.  This event permits translocation of NFAT to the 
nucleus where it interacts with other transcriptional partners to regulate gene expression 
(237).  NFAT family members may be transcriptional activators or repressors depending 
upon the genetic context.  For example, NFAT1 has been shown to repress the 
transcription of cyclin-depdendent kinase 4 (CDK4) and cyclin A2 (238, 239), both of 
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which serve critical functions in cell-cycle regulation and cell proliferation, while 
upregulating genes involved in immune function, such as interleukin-2 (IL-2) (240).  
Based on the ability of β4 to upregulate NFAT family members and to promote an 
invasive phenotype, we examined the hypothesis that this factor serves as a 
transcriptional repressor of miR-29a.  Interestingly, a report published around this time 
revealed that NFATc3 promotes the transcription of miR-23a in a model of cardiac 
hypertrophy (241), demonstrating that members of this transcriptional family can regulate 
the expression of miRNAs.  Analysis using Genomatix MatInspector software identified 
four putative binding sites for NFAT1 in the 3Kb region upstream of the miR-29b-1/a 
transcription start site (242).  Nonetheless, chromatin immunoprecipitation (ChIP) 
experiments in the MDA-MB-435/β4 transfectants failed to demonstrate that NFAT1 
could bind any of these sites.  Moreover, treatment of these cells with pharmalogical 
agents FK506 and cyclosporine A, inhibitors of calcineurin function, did not induce 
expression at this locus as assessed by expression of mature miR-29a and miR-29b.  
During the course of our study, a report was published characterizing 
transcriptional regulation at the miR-29b-1/a locus.  Mott et al. demonstrated that c-myc, 
hedgehog, and NFκB can bind the promoter of the miR-29b-1/a cluster and induce 
transcriptional suppression as established by elecrophoretic mobility shift assays, 
signaling inhibition, and a luciferase reporter construct (243).  
In retrospect, our finding that NFAT did not repress transcription at the miR-29b-
1/a locus downstream of β4 in the MDA-MB-435 system was not surprising given the 
fact that β4 may not actually function to repress transcription of this cluster based on the 
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observation that loss of the integrin decreased the expression of miR-29 family members 
in two other breast carcinoma cell lines.  While expression of β4 clearly appears to 
impact these miRNAs, the role of the integrin in this process appears complicated and 
context dependent.  To delve deeper into the issue, we employed the miR-29b-1/a 
promoter luciferase reporter construct developed by Mott et al. mentioned above to 
determine whether β4 repression of transcription at this site could account for reduced 
levels of mature miR-29a observed in MDA-MB-435/β4 transfectants.  The results were 
again surprising.  While expression of both miR-29a and miR-29b is downregulated in 
the β4 transfectants compared to mock transfectants based on the qNPA microarray and 
qPCR, increased transcriptional activity was detected at the miR-29b-1/a promoter in the 
β4 transfectants compared to the mock transfectants (data not shown).  Moreover, these 
data complement observations that ligation of β4 by antibody-mediated clustering 
modestly increased mature miR-29a levels in the β4 transfectants on a few occasions 
(data not shown).   
 Due to this unexpected result and concerns regarding the artificial nature of these 
luciferase experiments, we considered the possibility that our data were not accurately 
reflecting activity at the endogenous promoter.  Reports have linked cancer to 
inappropriate methylation of CpG islands in miRNA promoters (126, 244).  Along these 
lines, evidence in the literature indicates the presence of one CpG-enriched site 
containing five CpG nucleotide pairs in the promoter of this cluster, and that expression 
of these miRNAs can be linked to epigenetic modifications at this island (245).  Based on 
these observations, we could postulate that β4 induces changes in the methylation profile 
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at this CpG site to induce transcriptional silencing in the MDA-MB-435 system.  While 
β4 itself undergoes complex epigenetic modifications during the EMT (246), the integrin 
has never been shown to regulate such modifications in downstream targets nor induce 
the activity of enzymes involved in this process.  Bisulfite sequencing of this site in mock 
and β4 transfectants would prove informative in this context.   
While the luciferase data and ligation data corroborate the results from the array 
analysis and qPCR in the SUM-159 and MCF10CA1a cells, the disconcordance between 
promoter activity and mature miR-29a and miR-29b levels in the MDA-MB-435 system 
suggests some post-transcriptional phenomenon unique to these cells.  One possibility is 
that the exogenous β4 integrated into the genome in a position that somehow affected 
miR-29a biogenesis.  This hypothesis is unlikely given the fact that the integrin 
undergoes random integration into the genome, and two independent subclones both 
demonstrate repressed levels of miR-29a.  Though unlikely, it is possible that some 
selective advantage was conferred to subclones in which the integrin integrated in a 
particular position.  In this situation, perhaps integration might interrupt processing 
machinery genes, for example, involved in miR-29a biogenesis.  This is also unlikely 
given the fact that our analysis of the published Affymetrix array data showed no change 
in the several genes critical for miRNA maturation (data not shown).  It is further 
unlikely given the fact that the same machinery processes nearly all miRNAs, and the 
effect of β4 expression on miRNA patterns is not global enough to claim widespread 
defects in miRNA biogenesis.   
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Another hypothesis that could account for this incongruity is that the MDA-MB-
435 system is unique in its ability to impact miRNA stability.  Perhaps β4 generally 
upregulates expression of these miRNAs but in this system also promotes their decay or 
interferes with their biogenesis.  The most well studied example of miRNA decay 
involves regulation by LIN-28.  Interestingly, high levels of pri-let-7 transcript are 
detected in embryonic stem cells (ESCs) and other progenitor cells despite low levels of 
the mature miRNA (247).  This discrepancy results from a processing defect in which 
LIN-28 binds to the hairpin region of the primary miRNA and impedes cleavage by 
Drosha (248).  Interaction of LIN-28 with pre-let-7 can also prevent Dicer-mediated 
cleavage.  Specifically, LIN-28 recruits TUT4, a terminal poly(U) polymerase, and 
induces 3’-terminal polyuridylation of the precursor, which blocks processing by Dicer 
(249-253).  The uridylated precursor is then targeted for degradation by an unknown 
RNase (251).   
Though this phenomenon has only been reported in let-7 family members (248, 
251), it is feasible that a mechanism affecting miR-29a stability could account for low 
levels of the mature miRNA.  Decay of miR-29b, for example, has already been 
described in cycling HeLa cells, wherein the miRNA is subject to nuclear localization 
and rapid degradation resulting from a unique trafficking motif on its 3’ end (200).  Of 
particular interest, members of the let-7 family of miRNAs were determined by our 
analyses to be downregulated in response to β4 expression (Table 2.2).  Furthermore, let-
7 is thought to function as a tumor suppressor, targeting oncogenes such as myc (254).  
This factor has been linked to the transcriptional repression of the miR-29b-1/a cluster 
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(243), raising the possibility that β4 indirectly regulates miR-29a through a mechanism 
involving let-7.  Regardless of the mechanism by which low mature miR-29a levels are 
generated in the MDA-MB-435/β4 transfectants, analysis of primary and presursor levels 
of the miRNA would be enlightening.  For example, if expression profiles of pri-miR-29a 
across β4 and mock transfectants paralleled the luciferase promoter activity, but levels of 
pre-miR-29a were equivalent to mature levels, we would conclude that processing of the 
primary miRNA by the Drosha microprocessor did not proceed as expected.  The effect 
of clustering on transcriptional activity at the miR-29b-1/a locus as assessed by the 
luciferase reporter construct could also potentially clarify these discrepant data. 
Another possibility is that cells null for β4 express unusually high levels of miR-
29 family members, and that introduction of the integrin into the system represses its 
expression.  Over time, other mechanisms evolve to maintain suppression, and the 
integrin assumes a positive role in their regulation rather than a negative one.  This 
hypothesis is consistent with our observation that miR-29a correlates with β4 status in a 
collection of breast carcinoma cell lines (Fig. 3.2D).  This hypothesis that β4 can buffer 
miR-29 levels is intriguing, though information pertaining to absolute levels of the 
miRNAs would be useful in testing this idea.  Deep sequencing could provide more 
specific information in this direction.  It would further be of interest to determine whether 
a correlation exists between the amount of functional integrin in a cell and resulting 
levels of miR-29 family members.  Additionally, SUM1315 cells, which do not 
endogenously express the integrin, could be used to generate β4 transfectants.  If this 
hypothesis were correct, cells expressing β4 should have lower levels of miR-29 than 
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SUM1315 parental cells.  Unfortunately, developing cell lines that express functional β4 
is not a trivial task, because the integrin must be appropriately trafficked to the membrane 
and expressed at physiological levels to recapitulate behavior observed in cells that 
endogenously express it.  One flaw with the buffering hypothesis is the fact that most 
epithelial cells and many breast carcinomas express β4, so repression of miR-29a in 
response to the integrin may not be biologically relevant with respect to β4-mediated cell 
motility. 
The hypothesis that β4 actually sustains expression of miR-29 family members 
challenges our interpretation of their role in carcinoma invasion.  Clearly, our data and 
others have established a role for repression of miR-29a in the invasive process both in 
vitro and in vivo (255, 256).  Furthermore, the level of miR-29a in β4 positive tumors is 
significantly reduced compared to β4 negative tumors in the qNPA microarray (Table 
S2.3), and it is very well established that β4 promotes invasion.  One possibility is that 
miR-29a undergoes differential regulation by β4 to enhance cell motility depending upon 
the context.  For example, repression of miR-29 might permit enhanced expression of 
genes like matrix metalloproteinases (MMPs) involved in promoting invasion in some 
settings, while increased miR-29 might block genes that mediate cell adhesion in focal 
contacts.  Thus, miR-29 promotes an invasive phenotype but accomplishes this end 
through selective regulation of different genes pools.  Clearly many molecules have dual 
biological functions; integrins are a prime example, as they mediate stable adhesions but 
also facilitate cell motility and cytoskeletal dynamics.  
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The exact nature of the biological contexts in which miR-29 family members 
could be differentially regulated by β4 remains to be seen.  Perhaps integrin conformation 
contributes to this process.  It has been established that the MDA-MB-435 system can 
function in a ligand-independent manner, as discussed in Chapter I.  One possibility 
extending from these observations is that the integrin is in an active conformation with an 
open headpiece at the cell surface or is constitutively active due to a mutation that 
prevents association of the transmembrane legs of the α and β subunits.  Such events 
could promote signaling cascades not observed in cells in which the integrin is 
endogenously expressed and unbound by ligand.  Crystallography to ascertain the 
conformation of the integrin at the cell surface in the β4 transfectants, however, is 
obviously not a useful pursuit.   
Perhaps an easier, though less structurally informative, approach to determining 
whether β4 is constitutively active in the β4 transfectants would be to examine basal 
levels of signaling intermediates in pathways known to be activated by the integrin.  
Notably, levels of pAkt and p4E-BP1 are elevated in the β4 transfectants compared to 
mock transfectants in the absence of ligand (95). This raises the question as to whether 
activation of signaling pathways occurs in response to transfection as a sort of stress 
response, since it has been established that p85, the catalytic subunit of PI3K, can play a 
role in activating JNK (c-Jun N-terminal kinase) stress pathways (257).  However, levels 
of signaling intermediates in cells that have been depleted of endogenously expressed β4 
are also diminished (255).  These observations refute the hypothesis that constitutive 
activity of the integrin is unique to the β4 transfectants, thus, accounting for the 
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biological context in which miR-29a is differentially regulated.  These data do, however, 
strongly suggest that secretion of endogenous ligand plays a role in β4 signaling across 
systems, perhaps accounting in part for the phenomenon of ligand-independent signaling 
and function to be discussed below.  Nonetheless, it is likely that autocrine laminin does 
not entirely justify the ligand-independent function as evidenced by the fact that a 
truncated β4 containing only the transmembrane and cytoplasmic domains still confers 
signaling potential (69, 88). 
What likely matters more in the regulation of miR-29 family members is the 
larger biological context.  As described in the second chapter of this dissertation, β4 
expression correlates with differential expression of many miRNAs and miRNA families.  
The idea that β4 can regulate networks of miRNAs, which in turn regulate pools of target 
genes is likely a more physiologically accurate depiction.  These networks are important 
for fine-tuning gene expression and coordinating specific cellular functions, thus 
examination of a single miRNA might not prove very practical or informative.  
Along these lines, targeting of large gene pools by miR-29a is likely more 
biologically accurate than the idea that miR-29a regulates a single downstream target, 
such as SPARC, to promote invasion.  Inspection of putative targets of this miRNA 
reveals a number of potentially interesting genes.  Among these, three laminin chain 
isoforms are predicted targets of miR-29a: α2, γ1, and γ2.  In fact, a report exploring the 
role of family member miR-29c in nasopharyngeal carcinoma confirmed that γ1 is a 
bonafide target of the miRNA (258).  Laminins are heterotrimeric glycoproteins 
composed of a single α, β, and γ chain that assemble in a cross-like configuration (259).  
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Nomenclature for this family of proteins derives from the isoform of each chain, e.g. 
laminin-332 represents α3, β3, and γ2 (260).  The γ1 and γ2 chains are intriguing targets 
based on their links to carcinoma progression.  Specifically, overexpression of laminin-
511 correlates with the aggressive phenotype of invasive breast cancers (261, 262).  
Overexpression of laminin-332 is associated with poor prognosis in a variety of cancers, 
though the role of this isoform in breast cancer is less clear.   While downregulation of 
laminin-332 has been reported (263), a recent article identified elevated levels of the 
isoform, in particular the γ2 chain, in the interface zone of invasive ductal carcinoma 
(264).  
The hypothesis that β4 could regulate secretion of its own ligand through a 
miRNA-dependent mechanism is an intriguing idea, particularly given the report that the 
integrin functions in a laminin-332 autocrine loop to promote survival of anchorage-
independent breast carcinoma cells in a three-dimensional environment (98).  Neoplastic 
cells are believed to secrete their own matrix proteins (265, 266), conferring a selective 
advantage in the metastatic environment.  This phenomenon could revise our 
understanding of the ligand-independent function attributed to β4 in tumor cells, which 
might in part represent an autocrine loop involving secretion of endogenous laminin, 
subsequent ligand-binding, and integrin activation.  Such a pathway could provide a 
novel mechanism for β4-mediated carcinoma invasion.  Interestingly, a report from the 
literature indicates that laminin-332, the preferred ligand for β4, is not expressed in 
MDA-MB-435 cells (267).  In concordance with this study, our examination of the γ2 
chain of laminin in both β4 and mock transfectants revealed nearly undetectable levels of 
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the protein.  Furthermore, inhibition of miR-29 in the mock transfectants using a 
functional inhibitor failed to induce γ2 expression (data not shown).  Perhaps this is not 
surprising since these cells do not express β4 endogenously and might not have, 
therefore, evolved mechanisms to signal through the integrin in an autocrine manner.  
These cells do express α6β1, though, another laminin-binding integrin.  Nonetheless, we 
examined a cell line that endogenously expresses the integrin, SUM-159 cells.  Again, 
manipulation of miR-29a in these cells had no effect on γ2 protein expression.  These 
observations do not negate the possibility β4 can potentiate carcinoma invasion through 
miR-29a-dependent regulation of laminin, as the γ1 chain present in laminin-111 and 
laminin-511 might also function as a target, nor to they exclude the potential for β4 to 
execute this autocrine loop through regulation of another miRNA.  
Another potentially interesting target of miR-29a is p85, the regulatory subunit of 
the PI3K.  Perhaps elevated levels of phosphorylated Akt observed in the β4 transfectants 
are attributable to increased overall expression of the upstream lipid kinase.  A recent 
study reported that miR-29a targets p85, thereby inducing p53-dependent apoptosis in 
breast carcinoma cells (Park et al. 2009).  As before, no detectable difference in p85 
protein expression was appreciable between β4 and mock transfectants, and manipulation 
of miR-29a did not induce a change in p85 expression.  Furthermore, a point mutation in 
the p53 gene in these cells renders the tumor suppressor incapable of inducing apoptosis 
(93, 268).  A recent report does, however, suggest that β4 confers a proliferative 
advantage mediated by signaling through mitogen-activated protein kinase (MAPK) and 
Mnk (269).  Retrospectively, our observations that protein levels of both γ2 and p85 were 
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unchanged in the β4 transfectants compared to control is not surprising given the fact that 
our analysis of the published Affymetrix array failed to identify a change in transcript 
levels of these two genes, meaning that miR-29a-mediated regulation of their expression 
in this setting unlikely due to the fact that most miRNAs induce changes in mRNA levels 
that parallel changes in protein levels (125).    
 
SPARC 
Another major conclusion of this study is that β4 integrin expression and ligation 
can regulate the expression of SPARC in breast carcinoma cells, a phenomenon that 
further enhances our understanding of how β4 contributes to chemoinvasion.  Our data 
reveal distinct mechanisms by which β4 promotes SPARC expression.  Specifically, in 
cells lacking expression of the integrin, introduction of β4 decreases miR-29a levels 
while concomitantly increasing the expression of SPARC.  Ligation of the integrin in this 
system can further induce SPARC expression through a TOR-dependent translational 
mechanism.  Likewise, in cells that express β4 and, thus, low levels of the miRNA, 
ligation of the integrin also enhances SPARC translation.  Furthermore, SPARC is 
required for the invasive phenotype downstream of integrin β4.  Our observation that 
distinct mechanisms have evolved in cells to regulate SPARC expression downstream of 
β4 suggests that this event is biologically significant.    
While these data suggest that translational and miR-29a-mediated mechanisms 
occur independently to regulate SPARC expression, they do not exclude the possibility 
that these two phenomena may be functionally linked.  For example, miR-29a may 
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directly regulate SPARC by binding to its 3’UTR to silence expression, as well as target 
translational machinery involved in biosynthesis of the protein.  Interestingly, miR-100, 
one of two miRNAs downregulated across all three of our arrays in response to β4 
expression, has been shown to target mTor, a kinase involved in promoting cap-
dependent translation (270, 271).  Assessing the ability of β4 to induce SPARC 
expression upon ligation by laminin or antibody-mediated clustering in cells 
overexpressing miR-29a could help to explore this possibility.  
It is possible that β4 mediates SPARC expression through additional mechanisms.  
Early studies into the mechanism of β4-regulation of this protein included examination of 
other signaling pathways regulated by the integrin.  Specifically, we tested the effect of 
PD98059 on SPARC expression in the MDA-MB-435/β4 transfectants.  PD98059 is a 
potent inhibitor of MEK, a kinase upstream of ERK 1/2 in the Ras/MAPK pathway.  
Preliminary evidence suggests that expression of SPARC decreases upon treatment with 
the MEK inhibitor (data not shown).  Interestingly, a recent study reported that ribosomal 
S6 kinases RSK1 and RSK2 are effectors of the Ras/MAPK signaling pathway and 
induce an invasive phenotype in breast carcinoma cells in part through transcription 
factor FRA1 (272).  Earlier reports also link FRA1, a Fos homologue, to the migratory 
phenotype of breast carcinoma cells (273-275).  Such observations are particularly 
intriguing in light of the fact that c-Jun/FRA1 heterodimers can bind to the SPARC 
promoter in vitro (276), raising the possibility that β4 can signal through the 
Ras/MAPK/RSK pathway to induce FRA1-dependent transcription of SPARC.   
The possibility that β4 promotes SPARC transcription does not exclude miRNA-
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mediated or translational mechanisms.  In fact, computational analyses have recently 
confirmed the presence of type II circuits in mammalian cells, networks in which 
transcription of a miRNA and its target gene are oppositely regulated by upstream events, 
thereby reinforcing expression of the target gene (277).  This is consistent with the idea 
that miRNAs generally produce subtle effects on target gene expression (108), and that 
SPARC expression in the MDA-MB-435/β4 transfectants was dramatically increased 
(Fig. 3.1B).  Furthermore, a transcriptional phenomenon might be unique to the MDA-
MB-435 system, as depletion of β4 in the SUM-159s downregulated SPARC protein 
without affecting mRNA levels.  
As an aside, the use of signaling inhibitors to identify pathways through which β4 
represses mature miR-29a expression in this system was initially appealing.  While 
concerns regarding the half-life of the miRNA made interpretation of clustering 
experiments unfeasible, concerns about the stability of miR-29a are no longer at play in 
this context due to the fact that inhibition of signaling pathways would in theory increase 
expression of miR-29a.  Nevertheless, results were inconsistent across the board, and we 
were ultimately unsuccessful at derepressing expression of the miRNA through inhibition 
of any known pathways downstream of integrin β4. 
An intriguing, though somewhat unrelated, conclusion drawn from work on RSK 
as a downstream effector of Ras/MAPK involves the fact that integrin β4 is one of the 
pro-invasive genes whose expression is upregulated in response to signaling through this 
pathway.  As ligation of β4 can induce Ras/MAPK signaling, these observations raise the 
possibility that such an event could positively feedback to increase β4 transcription and 
114
expression, enhancing the biological potency of this integrin during carcinoma invasion.  
Although reports indicate that β4 induces activation of the Ras/MAPK pathway to 
promote carcinoma invasion (81), signal transduction through this pathway appears to be 
most significant in the context of anchorage-independent growth within the MDA-MB-
435 system (68).   
An extension of this hypothesis is that SPARC might also participate in a positive 
feedback loop and serve to modulate β4 expression and function.  SPARC is involved in 
a myriad of cellular processes, including the ability to regulate growth factor and integrin 
signaling pathways.  This phenomenon has been studied largely in the context of 
angiogenesis, where SPARC has been shown to bind VEGF-A and drive VEGF-
A/VEGFR2-mediated signaling and angiogenesis in a model of choroidal 
neovascularization (220, 278, 279).  SPARC is also known to directly bind PDGF family 
members to modify cell behavior (221, 280) and to indirectly regulate fibroblast growth 
factor 2 (FGF2)-induced signaling (281).  The role of SPARC in the regulation of TGF-
β1 signaling is also well established, as SPARC can either induce or antagonize signaling 
through this pathway depending upon the cellular milieu (226).   
Perhaps most interesting in the context of this dissertation is the ability of SPARC 
to affect integrin expression and signaling.  Interestingly, SPARC has been shown to bind 
β1, an integrin subunit that can pair with α6 as a laminin receptor, to induce signaling 
through integrin-linked kinase (ILK) in lens epithelial cells (224).  The ability of SPARC 
to induce ILK has also been extended to a glioma model, in which loss of SPARC 
impedes tumor cell survival and invasion associated with decreased ILK and FAK 
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activity (215).  SPARC-mediated regulation of ILK has also been shown to regulate 
extracellular matrix remodeling (222).  Furthermore, SPARC can induce integrin-
mediated migration in both prostate carcinoma and dental pulp cells through interaction 
with αV integrin family members (282, 283).  Other data, to the contrary, suggest that 
SPARC can antagonize the expression of α6 (284) and αV (285) integrins in different 
settings.  These observations coupled to the fact that SPARC can promote signaling 
through PI3K (213, 286) raise the possibility that interaction of SPARC with cell surface 
receptors or even β4 could induce expression or signaling events downstream of this 
integrin. 
Along the lines of feedback loops, SPARC could potentially function to impact 
the expression of miR-29 family members.  While miRNAs are classically thought to 
participate in unidirectional gene regulation, accumulating evidence reveals that feedback 
loops involving miRNA targets function to regulate the expression of select miRNAs 
through complex regulatory networks (287).  While SPARC has not been linked to 
signaling pathways implicated in miR-29b-1/a transcriptional repression, namely c-myc, 
hedgehog, and NFκB, additional investigation may establish a connection between 
SPARC and these transcriptional effectors.  Alternatively, further characterization of the 
miR-29b-1/a promoter may identify other factors that participate in the regulation of 
miR-29 family members downstream of SPARC-mediated signaling events.  
Further evidence that β4 can regulate SPARC through various mechanisms stems 
from the MDA-MB-435 TrkB system generated previously by our laboratory.  TrkB is a 
cell surface receptor involved in neuronal guidance and is analogous in many ways to 
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integrins (288).  Interestingly, brain-derived neurotrophic factor (BDNF), the ligand for 
TrkB, shares similarities with laminin (289).  A chimeric receptor was generated by 
fusing the TrkB extracellular domain to the cytoplasmic and intracellular domains of β4.  
A truncated TrkB construct consisting of the extracellular and cytoplasmic domains of 
this neuronal receptor was generated as a control.  The results of functional analyses 
using this TrkB system revealed that the cytoplasmic domain of β4 contains intrinsic 
signaling potential but is not sufficient to transduce all signals that have been attributed to 
the full-length integrin (69).  Specifically, upregulation of the SFK signaling pathway 
occurs in response to dimerization of the chimeric receptor, while induction of PI3K and 
Ras/MAPK signaling pathways are not detectable.   
We chose to examine SPARC expression in the TrkB system.  Surprisingly, our 
analysis revealed that TrkB β4 infectants express higher levels of SPARC in both the 
total cell lysate and the culture media compared to cells expressing the truncated TrkB 
construct (data not shown), suggesting that neither the extracellular domain nor ligation 
of the integrin by laminin are required for β4-regulation of SPARC.  Moreover, due to the 
fact that Akt phosphorlyation is not induced by dimerization of the chimeric receptor, it 
seems unlikely that the changes in SPARC expression could be attributable to a TOR-
dependent translational mechanism, as Akt is a kinase upstream of 4E-BP1 in the mTOR 
signaling pathway.  Instead, members of the Src family of kinases might contribute to 
SPARC regulation.  Notably, treatment of MDA-MB-435/β4 transfectants with PP2, an 
inhibitor of SFKs, failed to consistently decrease SPARC expression; however, these 
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cells are inherently different than the TrkB β4 system and may employ different 
mechanisms to regulate SPARC.  
Palmitoylation of β4 is critical for trafficking of the intergrin to tetraspanin-
enriched microdomains on the cell surface.  This process, in turn, permits cell spreading 
and signaling through p130 Crk-associated substrate (p130CAS) (63), an integrin adapter 
protein involved in cytoskeletal remodeling, focal adhesion turnover, and cell migration 
(290).  This signaling intermediate is often phosphorylated by members of the Src family 
of kinases and FAK (290).  Along these lines, it would be interesting to determine 
whether β4 palmitoylation and localization in tetraspanin-enriched microdomains 
promotes SPARC expression, as data from the TrkB/β4 system suggests a role for SFKs 
in β4-mediated regulation of this protein.   
Integrin β4 has been shown to cooperate with growth factor receptors to promote 
activation of signaling cascades and carcinoma invasion.  These findings prompted us to 
consider the possibility that β 4-regulation of SPARC, and in turn invasion, occurs 
through collaboration with another cell surface receptor.  Work previously published by 
our laboratory investigated the ability of specific factors to cooperate with β4 to promote 
the chemotaxis of MDA-MB-435/β4 transfectants.  Of the growth factors examined, 
including EGF, basic fibroblast growth factor, HGF, insulin-like growth factor type I, 
TGF-α and -β, PDGF (AA and BB), somatostatin, thrombin, and lysophosphatidic acid 
(LPA), only LPA induced chemotaxis at levels comparable to NIH-3T3 conditioned 
media (78).  Furthermore, this factor induced the formation of large ruffling lamellae, a 
phenomenon specific to the β4 transfectants.  Findings from this study and others suggest 
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that LPA binds heterotrimeric Gi proteins on the cell surface of the MDA-MB-435 cells 
to mediate these effects (78, 291).  Based on the data reported in this study, we tested 
whether LPA could induce SPARC expression in these cells.  Despite observing the 
appropriate morphological changes in response to LPA treatment, we did not detect an 
increase in SPARC expression (data not shown), raising the likely possibility that β4 
functions independently to regulate this downstream effector. 
A remaining question generated from our work involves the mechanism by which 
SPARC promotes invasion.  One likely possibility, as explored above, involves its ability 
to mediate integrin dynamics and expression.  Moreover, SPARC is known to induce 
signaling pathways important for invasion, such as PI3K.  Whether such signal 
transduction occurs in concert with integrin function remains to be seen.  Another 
possibility is that SPARC is involved in focal adhesion turnover.  Early studies 
examining the ability of SPARC to impact interactions between cells and their 
environment established that addition of this counter-adhesive protein to bovine aortic 
endothelial cells decreases the formation of focal adhesions and promotes redistribution 
of actin to peripheral regions of the cell (292).  Given these findings, as well as the fact 
that SPARC can induce the activity of FAK, the primary signaling protein involved in 
focal adhesion turnover, it is possible that SPARC functions downstream of β4 in this 
capacity to promote cell motility.  Regulation of MMPs is another likely path through 
which SPARC promotes invasion.  Members of this family of proteolytic proteins are 
considered to be the primary regulators of matrix proteolysis and turnover, and their role 
in promoting the invasive behavior of tumor cells is well established (293).  SPARC is 
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known to induce activity of MMPs through a direct interaction with α helices of its E-F 
hand region (294).  In breast cancer, SPARC is known to upregulate MMP-2 activation 
(210), giving rise to the possibility that β4-induced expression of SPARC functions to 
activate MMPs involved in promoting invasion. 
 
Concluding Remarks 
 The work presented in this dissertation enhances our understanding of integrin 
function and regulation of downstream effector molecules.  Specifically, our data define a 
novel role for β4 in promoting cell motility in breast cancer.  Expression of this integrin 
correlates with distinct miRNA patterns, potentially important for driving cell behavior 
downstream of the integrin.  Additional work is necessary to dissect the mechanism by 
which β4 induces differential expression among members of this regulatory class of small 
RNAs.  Whether such effects arise through transcriptional changes, modifications in 
biogenesis, or influences on stability remains to be seen.  Furthermore, characterizing 
more fully the contribution of miRNAs to the invasive process will be of value, 
particularly through identification and confirmation of downstream targets aside from 
SPARC.  While this study has focused on the ability of differentially expressed miRNAs 
to potentiate an invasive phenotype in carcinoma cells, future work will investigate the 
ability of such miRNAs to participate in other functions mediated by β4 integrin, 
including hemidesmosome organization, anchorage-independent growth, and cell 
survival. 
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  While the material presented in this dissertation explores the role of β4 integrin in 
the context of carcinoma progression, specifically in the process of invasion, it has been 
well established that the integrin functions under normal conditions to maintain 
homeostasis.  For example, in the breast, β4 is expressed in contractile myoepithelial cells 
that separate the secretory luminal cells of mammary alveoli from the underlying 
basement membrane (295), whereas in the skin, the integrin is expressed in basal 
keratinocytes at epidermis-dermis interface and maintains epithelial integrity (40, 41).  
Studies exploring the mechanisms that mediate wound closure in keratinocytes have 
established an important role for β4 in this phenomenon, one that necessitates effective 
cell migration and parallels the process of tumor cell invasion (38).  The idea that SPARC 
or specific miRNAs might play a role in reepithelialization or maintaining general 
homeostasis is intriguing.  Monitoring changes in the expression of these effector 
molecules in keratinocytes during a scratch assay, which functions as an in vitro method 
of monitoring cell migration, could shed light on this question.  Furthermore, the ability 
of SPARC or specific miRNAs to modulate wound closure in this setting could be 
assessed following manipulation of their expression levels.   
From a clinical standpoint, the idea of miRNAs as targets in cancer therapeutics 
has gained increasing attention.  The recognition that aberrant miRNA expression 
contributes to human disease has prompted an interest in the development of strategies 
aimed at correcting the inappropriate deficiency or accumulation of specific miRNAs.  In 
most cancers, miRNA expression is globally downregulated.  Targeted therapies will, 
therefore, likely focus on reintroduction of select miRNAs and augment current 
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chemotherapeutic regimes.  Delivery of these agents could be accomplished through 
infection of cancer cells using viral vectors that encode short hairpin RNAs; these 
hairpins would be subject to processing by endogenous miRNA biogenesis machinery 
upon transcription (296).  Advances in this field of research may ultimately hinder cancer 
progression and improve prognosis and outcome in patients with aggressive disease. 
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